



Final Programme

---

# 11<sup>th</sup> EACPT Congress 28 - 31 August 2013

---

Geneva  
Switzerland

---



## **Welcome Message**

4

## **Committees**

5

---

## **General Information**

6-8

---

## **Social Programme**

9

## **Exhibitors & Sponsors**

10

## **Awards and Recognition**

11

## **Programme Overview**

12-13

## **Plenary Speaker Biographies**

14

---

## **Scientific Programme**

16-28

## **Poster Presentations**

29-43

---

## **Exhibition Floor Plan**

44

## **Congress Centre Floor Plan**

44-45

## **Congress Centre – Access Map**

46

# Dear Colleagues

It is a great pleasure to welcome you to the 11th Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT) in Geneva. Under the auspices of the Swiss Society of Clinical Pharmacology and Toxicology and the other sponsors, the Congress will take place from 28 to 31 August 2013 at the International Conference Center Geneva (CICG), in the smallest of the world class metropolis.

Clinical pharmacology provides a wide array of services, from excellence in patient care, teaching and clinical research to high standard efficient contribution in drug development and professional services in regulatory bodies.

The Congress is a unique opportunity to meet top ranking specialists of various professional backgrounds involved in drug discovery, drug development, pharmacology and pharmacotherapy teaching, drug use, drug epidemiology, and drug safety.

I hope that the exciting topics proposed in the program stimulate your interest.


Thank you for joining us in Geneva.

On behalf of the organizing committee,  
Best Regards,



Professor Pierre Dayer, MD  
Congress President

A handwritten signature in blue ink, appearing to read 'P. Dayer', located below the printed name of the Congress President.



# National Organizing Committee

## Congress President

- Prof. Pierre Dayer, Geneva

## Co-Chairs

- Dr Marie Besson, Geneva
- Dr Caroline Samer, Geneva

## Members

- Dr Edoardo Baglivo, Geneva
- Dr. Marie Besson, Geneva
- Prof. Thierry Buclin, Lausanne
- Prof. Chantal Csajka, Lausanne
- Dr. François Curtin, Geneva
- Dr. Youssef Daali, Geneva
- Prof. Pierre Dayer, Geneva
- Prof. Jules Desmeules, Geneva
- Dr. François Girardin, Geneva
- Dr. Markus Hodel, La Chaux-de-Fonds
- Dr. Ilse Kern, Geneva
- Dr. Mitsuko Kondo Oestreich, Geneva
- Prof. Dr. Gerd A. Kullak-Ublick, Zurich
- Dr. Hugo Kupferschmidt, Zurich
- Dr. Shanthi Narayan Pal, Geneva
- Dr. Caroline Samer, Geneva

# International Advisory Board

- Dr. Nina Bjarnason, Denmark
- Prof. Ylva Böttiger, Sweden
- Prof. Kim Brøsen, Denmark
- Prof. Gonzalo Calvo Rojas, Spain (EACPT chair)
- Prof. Ingolf Cascorbi, Germany
- Prof. Kari Kivistö, Finland (EACPT treasurer)
- Prof. Simon R. J. Maxwell, United Kingdom
- Prof. Gerard Rongen, The Netherlands
- Prof. Matthias Schwab, Germany
- Prof. Tabassome Simon, France (EACPT vice-chair)
- Prof. Donald Singer, United Kingdom (EACPT secretary)
- Prof. Edoardo Spina, Italy
- Prof. Zoltan Szekanez, Hungary
- Prof. Adam Vas, Hungary
- Prof. Dinko Vitezic, Croatia
- Prof. Theo de Vries, The Netherlands
- Prof. David Webb, United Kingdom

## Opening hours of the registrations

Wednesday 28 August 2013	07:30 – 19:00
Thursday 29 August 2013	08:00 – 18:30
Friday 30 August 2013	08:00 – 18:30
Saturday 31 August 2013	08:30 – 11:30

## Opening hours of the exhibition

Wednesday 28 August 2013	10:00 – 17:30
Thursday 29 August 2013	10:00 – 17:30
Friday 30 August 2013	10:00 – 17:30

## Congress Venue

All scientific sessions, poster presentations, industry exhibition, coffee breaks and lunches will be located in the Centre International de Conference de Genève (CICG) see access plan page 46:

**17 rue de Varembe  
CH – 1211 Genève 20**

## Speakers

All speakers are asked to visit the Speaker Preview Room located on Level 0, behind the "Bar Léman" (coffee bar), no later than two hours before their presentation.

Wednesday 28 August 2013	07:30 – 19:15
Thursday 29 August 2013	08:00 – 19:00
Friday 30 August 2013	08:00 – 19:00
Saturday 31 August 2013	08:00 – 12:00

## Official language

The sessions and congress materials will be available in English. No interpretation nor translation will be provided.

## Certificate of Attendance

A Certificate of Attendance will be provided to you with your congress materials if you pre-registered for the Congress. For on-site registrants, a Certificate of Attendance will be provided as quickly as possible but participants may be asked to return at a quiet period to collect their certificate. No certificates will be issued after the Congress.

## Disabled persons

The CICG offers a full range of amenities to assist those with disabilities. Lifts are also at the disposal for those with disabilities. For further information or assistance please go to the Congress Information Desk on Level 0.

## Use of cameras and telephones

The use of any type of audio or visual recording equipment is not permitted during any of the scientific presentations. This includes the use of video or digital cameras to record speaker slide presentations. Cell/mobile phones must be on silent or diverted for all Congress sessions.

## No Smoking

The CICG is a smoke-free facility. No indoor smoking areas are provided.

## Name badges

Security is strict in the CICG. You will need to wear your delegate name badge at all times. This will identify you to Congress colleagues, door and catering staff. Delegates who do not display the appropriate name badge will not be permitted to enter the CICG. Lunch and coffee break services will only be available to delegates registered for the full Congress, or for that particular day.

## Catering points

Lunch will be served every day from the restaurant area on Level 1. Coffee stations will be available in the exhibition area on Level 0 of the CIG. For break times, please see daily programme schedules.

## Cloakroom

A cloakroom service is available for participants on Level 0. Please make sure that no personal belongings are left after closing each day. All items are left at the owner's risk. Opening hours:

Wednesday 28 August 2013	07:30 – 20:15
Thursday 29 August 2013	08:00 – 20:00
Friday 30 August 2013	08:00 – 18:45
Saturday 31 August 2013	08:30 – 12:15

## Emergency and assistance on site

In case of emergency, or if you require any assistance, please contact the staff at the Information Desk on Level 0. A medical room is located on Level -1 and will be staffed by medical personnel throughout the congress.

## Poster Boards

All poster boards are located on Level 0 of the CIG.  
**Poster Presenters are requested to hang their poster between 08:00 – 10:00 on Wednesday 28 August 2013.** All posters will be displayed for the duration of the congress. Presenters are requested to leave their poster on display until 11:15 on Saturday 31 August 2013. Presenters are responsible for removing their own poster. Any poster not removed by 12:30 on Saturday 31 August 2013 will be removed and disposed of. No posters will be retained by the organisers and/or returned to presenters.

Presenters are required to stand by their poster for their Poster Guided Tour on the relevant day and time. Poster guided tours will take place at the following times:

Wednesday 28 August 2013	12:30 – 13:30
Thursday 29 August 2013	12:30 – 13:30
Friday 30 August 2013	12:30 – 13:30
Saturday 31 August 2013	10:30 – 11:15

## Computer terminals

There are computer terminals available on Level 0 at the venue for participants to use for internet access.

## Programme Changes

Organisers cannot assume liability for any changes in the programme due to external or unforeseen circumstances.

## Congress bag

We are pleased to announce that our EACPT 2013 delegate bag has been produced by Township Patterns, a social enterprise which designs, produces and markets a range of eco-friendly textile Congress bags in order to directly support the sustainable development of women-owned sewing cooperatives operating out of the townships of South Africa.

Township Patterns is a fair trade, WFTO ([www.wfto.com](http://www.wfto.com)) accredited company and supplies customers world-wide.

## Registration Fees (on-site registrations)

Registration Type	From 22 August 2013
Congress Delegate (Member of an affiliated society)	900 CHF
Congress Delegate (Non-Member of an affiliated society)	950 CHF
PhD Student	430 CHF
Qualified Participant from Developing Countries	430 CHF
Day Ticket (all categories)	350 CHF

## ☛ Liability and insurance

Neither the organisers nor EACPT will assume any responsibility whatsoever for damage or injury to persons or property during the Congress.

## ☛ Accommodation

The hotel desk is located in the registration area on Level 0. Please visit the hotel desk to make or amend a reservation during your visit to the Congress.

## ☛ Registration fee for regular participants and students includes

- Access to scientific presentations, poster presentations, congress material, abstracts online
- Access to the exhibition
- Opening Plenary and Welcome Reception (Wednesday 28 August 2013)
- Daily lunches at congress venue (3 days)
- Coffee breaks
- Cultural event on Thursday evening (29 August 2013 at the CIGC)

## ☛ Internet

An internet corner is located in the exhibition area. Wi-Fi connection is also available in the conference venue. Wireless internet access is available to all participants in the conference venue. Personal access codes are provided together with the badge and here below:

Username: EACPT

Password: 2013

## ☛ Organising Secretariat

### EACPT 2013

C/o MCI Suisse SA  
Rue de Lyon 75  
P.O. Box 502  
1211 Geneva 13  
Switzerland



### REGISTRATION & ACCOMMODATION

Tel: +41 22 33 99 725

Email: [eacpt2013reg@mci-group.com](mailto:eacpt2013reg@mci-group.com)

## ☛ Acknowledgements

The Organising Committees would like to acknowledge the support of:



*World Health Organisation*



## ► Welcome Reception

Wednesday 28 August 2013 20:15

Venue: CICG, Level 0

All registered participants are invited to join us directly after the Opening Plenary for the Welcome Reception. The reception will take place on Level 0 of the CIG.

## ► Cultural Event

Thursday 29 August 2013 19:00

Venue: CIGG, Level 0

For those of you visiting Geneva or Switzerland for the first time, this will be the opportunity to get a taste of the Swiss culture. Those of you who have visited before, don't miss this opportunity to sample some fine Swiss chocolate and enjoy Alpine music with a modern twist. Participants will also be able to purchase Swiss chocolates during the event. This event is open to all registered participants.

## ► Congress Dinner

Friday 30 August 2013 20:00 – 22:30

Venue: aboard the boat "Lausanne" – cruise on lake Geneva

Meeting point: Embarcadère des Pâquis  
Quai du Mont-Blanc  
(Front of the Beau-Rivage Hotel)



Take this unique opportunity to join your colleagues and peers from throughout Europe for an informal moment of relaxation and the perfect chance to spend the evening aboard a cruise boat on the beautiful Lake Geneva. Enjoy drinks and a finger buffet whilst catching up with existing acquaintances and meeting new ones. Entertainment will be provided by Swiss band "Recall".



**Dress code: evening wear**

*Tickets are available from the registration area - space is limited so don't miss your opportunity to participate in this evening !*

➡ EACPT would like to thank the generous support of the Exhibitors & Sponsors at the 2013 Congress:

## SILVER



**Almirall**

*Congress Bags & Lanyard Sponsorship*

## BRONZE



**Gedeon Richter**

*Satellite Symposium*



**Società Italiana de Farmacologia**

*Satellite Symposium*



**Innovative Medicine Initiative (IMI)**

*Satellite Symposium*



**Novartis Pharma Schweiz AG**

*Exhibitor & Final Programme Advertising*

## OTHERS



**Astellas**

*Website Sponsorship*



**Merck (Schweiz) AG**

*Delegate Bag Insert*



**TRB Medica**

*Final Programme Advertising*



**British Pharmacology Society**

*Satellite Symposia and Exhibitor*

**WILEY**

**Wiley**

*Exhibitor*

## EACPT 2013 Poster Prizes:

The EACPT congress will be awarding one Poster Prize per day of CHF 1,000. The winning posters will be selected amongst those accepted and presented at the congress. All posters accepted and presented will be considered. Poster Prizes will be presented during the Closing Ceremony.

## EACPT Lifetime Achievement Awards Prof Sir Michael Rawlins and Prof Carlo Patrono

The 2013 Lifetime Achievement Award of the European Association of Clinical Pharmacology and Therapeutics goes jointly to **Professor Sir Michael Rawlins** and to **Professor Carlo Patrono**, for their outstanding contributions to the national and international benefits of clinical pharmacology for medicine, health care and patient safety.



Professor  
Sir Michael Rawlins

The awards will be presented on Friday 30 August 2013 during the plenary session in room 2 of the CICG, 11:45.



Professor  
Carlo Patrono

## EACPT Scientific Award Dr David Devos

The EACPT is delighted to announce that the 2013 EACPT Scientific Award goes to **Dr David Devos** from the Department of Medical Pharmacology at the Université Lille Nord, France. The EACPT Scientific Award is for the report by Dr Devos of a new approach to treating Parkinson's disease.

The paper, for which Dr Devos was corresponding author, was published in the July 2012 issue of the high impact international journal - *Lancet Neurology*, entitled:



Dr David Devos

'Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.'

The prize will be presented to Dr Devos on Thursday 29 August during the plenary session in Room 2 of the CICG, 11:45.

## EACPT Special Award Prof Michael Orme

The EACPT is delighted to announce a Special Award for services to the EACPT for **Professor Michael Orme**. Michael Orme was the first honorary secretary of EACPT from 1995-2003, chairman of the Education Sub-committee from 1997 to 2003, and chairman of EACPT from 2003-2007, remaining on the Executive Committee as past chairman until 2011.






Professor  
Michael Orme





In these roles Michael Orme brought his interests in European and global efforts of clinical pharmacology as a medical speciality devoted to the rational use of drugs, to growing EACPT into a major international organisation representing all clinical pharmacology societies in Europe.

The prize will be presented to Professor Orme on Thursday 29 August during the plenary session in Room 2 of the CICG, 11:45.





**WEDNESDAY 28 AUGUST 2013**

	Room 2	Room 3	Room 4
09:00 - 10:30	Predictive Pharmacogenetics	How to become a self-empowered patient	Updates in clinical toxicology
10:30 - 11:00	 Coffee Break		
11:00 - 12:30	Clinical trials methodologies	Special populations: prenatal pharmacology	Networking in Clinical Toxicology
12:30 - 13:30	 Lunch and Posters Guided Tour		
13:30 - 15:00	Health therapies assessment	Training tomorrow's prescribers	The use of molecular imaging biomarkers in drug development (EANM)
15:00 - 15:30	 Coffee Break		
15:30 - 17:00	Health issues and communication	Assessing and supporting tomorrow's prescribers (BPS)	Health economic assessment
17:00 - 17:30	Break		
17:30 - 18:30		Whats new in malaria therapeutics (WHO)	Current trends in Global Pharmacovigilance (WHO)
18:30 - 19:15	Plenary: Innate immune sensing of nucleic acids and application for oligonucleotide – based immunotherapy		
19:15 - 20:15	Opening ceremony		
20:15 - 21:00	Welcome reception		



**THURSDAY 29 AUGUST 2013**

	Room 2	Room 3	Room 4
09:00 - 10:30	Personalizing cancer therapy (with ASCPT)	New developments in TDM	Pharmacovigilance networks (WHO)
10:30 - 11:00	 Coffee Break		
11:00 - 11:45	Plenary: Anti-Angiogenic Therapy: New Insights		
11:45 - 12:00	EACPT Scientific and Special Awards		
12:00 - 13:30	 Lunch	Innovative Medicines Initiative	 Lunch
12:30 - 13:30	Posters Guided Tour		Posters Guided Tour
13:30 - 15:00	Clinical trials regulation, control, benefits	Inflammatory disease and Biotherapeutics	Drug Safety: from clinical trials to clinical practice (WHO)
15:00 - 15:30	 Coffee Break		
15:30 - 17:00	Frontiers in Pharmacology (BPS)	Ocular Pharmacology	Drug Safety in emerging countries (WHO)
17:00 - 17:30	Break		
17:30 - 19:00	Pharmacology of Chocolate	The dopamine D3 receptor as a potential target for psychiatric diseases (Gedeon Richter)	
19:00 - 21:00	Chocolate tasting and cultural event		

## FRIDAY 30 AUGUST 2013

	Room 2	Room 3	Room 4
09:00 - 10:30	Diabetes	PK/PD modelling	Who should initiate drug development?
10:30 - 11:00	 Coffee Break		
11:00 - 11:45	Plenary: Immune mechanisms of atherosclerosis		
11:45 - 12:00	EACPT Lifetime Achievement Awards		
12:00 - 13:30	 Lunch		
12:30 - 13:30	Posters Guided Tour		
13:30 - 15:00	Special cardiovascular pharmacology	Ethics	Special liver pharmacology
15:00 - 15:30	 Coffee Break		
15:30 - 17:00	Drug-drug Interactions	Advances in the treatment of rare diseases: expectations on advanced therapies	New targets for pain treatment
17:00 - 17:30	Break		
17:30 - 19:00	Future Challenges for Clinical Pharmacology in Health Care (WHO)	Methodological issues in clinical trials with CNS drugs (SIF)	
20:00 - 23:00	Gala dinner		

## SATURDAY 31 AUGUST 2013

	Room 2	Room 3	Room 4
09:00 - 10:30	Best abstract, oral communications	Doping: Sports and Pharmacologists	Neuro-Psychopharmacology: filling the gaps
10:30 - 11:00	 Coffee Break and and Posters Guided Tour		
11:15 - 12:00	Closing ceremony and poster awards		

## ☛ Prof. Gunther Hartmann, M.D.

Gunther Hartmann studied medicine at the University of Ulm. From 1994 to 1997, he worked as medical doctor at the University Hospital in Munich, Germany. In 1998 and 1999 he was postdoc in the laboratory of Arthur Krieg at the University of Iowa, USA. Back in Munich he became assistant professor at the Department of Clinical Pharmacology of the University of Munich where he established his research group Therapeutic Oligonucleotides. In 2005, he became head of Clinical Pharmacology of the University Hospital of Bonn. Since 2007, he is Director of the Institute of Clinical Chemistry & Clinical Pharmacology and the Central Laboratory in Bonn. Gunther Hartmann has been continuously working in the field of oligonucleotides since 1995. Major contributions were the characterization of the immunostimulatory activities of CpG oligonucleotides in the human immune system, the application of CpG oligonucleotides in animal tumor models, the analysis of immunological activities of siRNA and the responsible receptor TLR7 (Nat Med 2005) and the identification



of 5' triphosphate RNA as the ligand for the cytosolic antiviral helicase RIG-I (Science 2006). His prime interests are innate immunity, immune sensing of nucleic acids, and the development of oligonucleotides for the therapy of viral infections and cancer. He is Speaker of the DFG-funded Excellence Cluster "ImmunoSensation".

## ☛ Prof. Napoleone Ferrara, M.D.

Dr. Ferrara obtained his M.D. degree in 1981 from the University of Catania Medical School in Italy. After completing his postdoctoral research at the University of California at San Francisco, he joined Genentech Inc. in 1988. He spent nearly 25 years with the organization where his work on the isolation, molecular cloning and biological characterization of VEGF-A resulted in the development of bevacizumab, the first anti-angiogenic agent to be approved by the FDA for cancer therapy. His research there also led to the development of ranibizumab, which has been FDA-approved for the treatment of multiple intraocular neovascular disorders.



In December 2012, Dr. Ferrara joined the University of California, San Diego as a Distinguished Professor of Pathology and Senior Deputy Director for Basic Sciences of the Moores Cancer Center. He plans to continue his research focusing on the biology of angiogenesis and the identification of its regulators.

## ☛ Prof. Ziad Mallat, M.D.

Dr. Mallat received his MD and qualification in Cardiovascular Diseases from University of Pierre et Marie Curie, in 1996, and his Ph.D. in Cardiovascular Physiology from University of Paris-Diderot in 1999. He joined INSERM, Paris in 1998 as Assistant Research Professor, then became Associate Professor in 2002 and Research Professor in 2007. He is currently BHF Professor of Cardiovascular Medicine at the University of Cambridge, UK. He is on the Editorial Board of Circulation Research and Journal of Molecular Medicine, and is Associate Editor of Arteriosclerosis Thrombosis and Vascular Biology. He served from 2004 to 2008 as a scientific advisor to the General Director of INSERM, France. He is co-founder and consultant for ATEROVAX, a biopharmaceutical company.

Dr. Mallat has authored more than 100 scientific papers in peer-reviewed journals including New England Journal of Medicine, Nature Medicine, Journal of Clinical Investigation, Journal of Experimental Medicine, Circulation and Circulation Research. Dr. Mallat's early work identified apoptotic death within the atherosclerotic lesion as the major determinant of plaque-tissue factor activity. He then has been actively studying the cellular and molecular pathways involved in the regulation of the immuno-inflammatory response in atherosclerosis. Particularly, research from his laboratory has pointed to new major chemokine pathways involved in monocyte/macrophage recruitment and accumulation into atherosclerotic lesions, and identified a critical role for the regulatory arm of the adaptive T cell response in the control of lesion development. He has shown that defective clearance of apoptotic cells impairs the regulatory immune response in atherosclerosis and accelerates lesion development, suggesting an important interplay between innate and adaptive immunity in promoting lesion development

and progression. More recently, he has identified a pathogenic role for mature B cells in the development of atherosclerosis. Current research activities address the relation between autoimmune diseases and atherosclerosis, and the role of the regulatory immune response in the prevention and/or treatment of plaque vulnerability.







# TRB CHEMEDICA



## Swiss Quality in Health Care



Rheumatology



Ophthalmology



Neurology

# WEDNESDAY 28 AUGUST 2013

**09:00 – 10:30**

Room 2

## Predictive Pharmacogenetics

*Chairpersons:**Jules Desmeules, Ingolf Cascorbi***09:00**

**Genetics of treatment response  
in depression**  
Antonio Drago

**09:30**

**Pharmacogenetic and other factors  
in individualization of oral anti-vitamin k  
anti-coagulants**  
Philippe Beaune

**10:00**

**A promising predictor for heart diseases  
and diuretic drug therapy in the  
aldosterone receptor gene**  
Nawar Dalila

**10:15**

**CYP2R1 genetic polymorphisms are  
associated with lower 25-hydroxy  
vitamin D levels in Lebanese subjects**  
Nathalie Zgheib



Room 3

## How to become a self-empowered patient

*Chairpersons:**Christine Cedraschi, Donald Singer***09:00**

**Collection and impact of patient  
reported outcomes**  
Anne Viola

**09:30**

**Medication use: from leaflet to  
e-learning**  
Valérie Piguet

**10:00**

**How to govern a self-powered patient:  
privacy and biopower**  
Sami Coll



Room 4

## Updates in clinical toxicology

*Chairpersons:**Hugo Kupferschmidt, Gerald Rongen***09:00**

**Lipid emulsion as a new antidote -  
current use, extension from lipophilic  
local anesthetics to other drugs,  
and state of the art**  
Theodore C. Bania

**09:30**

**Challenges in paracetamol poisoning**  
Nicholas Bateman

**10:00**

**New insights into the mechanisms  
of dioxin toxicity in humans**  
Jean-Hilaire Saurat



**COFFEE BREAK**  
10:30 – 11:00

**11:00 – 12:30**

Room 2

## Clinical trials methodologies

*Chairpersons:**Thierry Buclin, Ylva Böttiger***11:00**

**Towards best reporting practices  
for clinical pharmacology trials**  
Doug Altman

**11:30**

**The future of modeling and simulation  
approaches in drug development**  
Marc Pfister



**12:00** Biases on the administered parenteral doses of an experimental drug during phase I clinical trials  
Nicolas Widmer

**12:15** Critical review of the validation process of six predictive biomarkers: how good is the quality and quantity of the evidence?  
Joaquin Saez Penataro

## Room 3 Special populations: prenatal pharmacology

*Chairpersons:*  
Victoria Rollason, Gerard Rongen

**11:00** TINN (Treat Infections In Neonates): an FP7 project  
Evelyne Jacqz-Aigrain

**11:30** Studying teratogenic effects of medication use during pregnancy: challenges and pitfalls  
Marleen van Gelder

**12:00** Pregnancy outcome following maternal exposure to mirtazapine: preliminary results of a collaborative entis study  
Ursula Winterfeld

**12:15** Fetal exposure to nonsteroidal antiinflammatory drugs and spontaneous abortions  
Sharon Daniel

## Room 4 Networking in Clinical Toxicology

*Chairpersons:*  
Hugo Kupferschmidt, Gonzalo Calvo

**11:00** The poisons centres networks - toxicosurveillance  
Herbet Desel

**11:30** Networking for regulatory toxicology  
Martin Wilks

**12:00** The Swiss model of comprehensive antidote provision  
Hugo Kupferschmidt



LUNCH & POSTERS GUIDED TOUR  
12:30 – 13:30



**13:30 – 15:00**



Room 2

## Health therapies assessment

*Chairpersons:*  
Francois Girardin, David Webb

**13:30** The role of the clinical pharmacologist in pharmacoconomics, health economics  
Michael Rawlins

**14:00** The Scottish model: Scottish Medicines Consortium (SMC)  
David Webb

**14:30** An assessment of the accuracy of horizon scanning predictions of medicine use in the scottish national health service  
Sharon Hems

**14:45** Dabigatran - demonstrates the need for comprehensive approaches to optimise the use of new drugs  
Brian Godman



Room 3

## Training tomorrow's prescribers

*Chairpersons:*  
Simon Maxwell, Theo De Vries

**13:30** The relevance of clinical workplace learning and assessment in CP&T  
Tim Dornan

**14:00** A systematic follow-up of student-prescribers (track): therapeutic knowledge, skills/competencies and attitude  
David Brinkman

**14:30** Assessment of clinical pharmacology skills as part of the new integrated final exam for medical students at Karolinska Institutet  
Marie-Louise Ovesjo

**14:45** The effect of a structured medical record on the recording of therapeutic information and communication between doctors  
Robert J. Van Unen



Room 4

## The use of molecular imaging biomarkers in drug development

(with the help of EANM)

*Chairpersons:*

Christer Halldin, Adam Vas

13:30

**Translational PET in Neuroscience and Drug Development**  
Christer Halldin

14:00

**The academia's view on collaboration with industry**  
Antony Gee

14:30

**Opportunities and challenges of molecular imaging collaboration in pharmaceutical development**  
Paul Maguire

14:45

**Interaction between industry and academia: Developing PET imaging tracer for Novel Targets**  
Gilles Tamagnan



COFFEE BREAK  
15:00 – 15:30



15:30 – 17:00



Room 2

## Health issues and communication

*Chairpersons:*

Pierre Dayer, Donald Singer

15:30

**Mediator (Benfluorex), a French and worldwide public health disaster**  
Irène Frachon

16:00

**Risk perception among healthcare professionals and the public: experience from regional medicines information and pharmacovigilance centres in Norway**  
Jan Schjøtt

16:30

**The risk–benefit relationship as a moral compass**  
Michel Lievre



Room 3

## Assessing and supporting tomorrow's prescribers

(sponsored by BPS)

*Chairpersons:*

David Webb, Phil Routledge

15:30

**Development of a UK national Prescribing Skills Assessment**  
Simon Maxwell

16:00

**Undergraduate training for medical students in CPT and prescribing**  
Sarah Ross

16:30

**Electronic solutions for safer hospital prescribing**  
Jamie Coleman

16:45

**Developing a standardised prescription chart to reduce error**  
Phil Routledge



Room 4

## Health economic assessment

*Chairpersons:*

Francois Girardin, Michael Rawlins

15:30

**The economics of personalised medicine and pharmacogenetic testing**  
Dyfrig Hughes

16:00

**Value Based Pricing to ensure cost effective drugs for the UK NHS: will it work?**  
Mark Sculpher

16:30

**Patented drug extension strategies on healthcare spending: a cost-evaluation analysis**  
Nathalie Vernaz

16:45

**Pharmacoeconomic drivers in pharmacogenomics**  
Stijn Vandekerckhove

BREAK

17:00 – 17:30



**17:30 – 18:30**

**Room 3**

## Whats new in malaria therapeutics

(sponsored by WHO)

*Chairperson:*  
Andrea Bosman

**17:30** Update on the status of artemisinin resistance  
Pascale Ringwald

**18:00** New medicines for control and elimination of malaria  
Timothy Wells

**Room 4**

## Current trends in Global Pharmacovigilance

(sponsored by WHO)

*Chairperson:*  
Lembit Rago

**17:30** Safety Information today and how can we improve patient safety tomorrow  
Andrzej Czarnecki

**18:00** Population pharmacogenetics and its implications for pharmacovigilance  
Adrian Llerena



**17:30 – 19:00**

**Room 13**

## SSCPT general assembly

*Private meeting*



**18:30 – 20:15**

**Room 2**

## Plenary: Innate immune sensing of nucleic acids and application for oligonucleotide – based immunotherapy

**Günter Hartmann**

*Chairperson:*  
Pierre Dayer

**Room 2**

## Opening ceremony

Pierre Dayer, Congress President  
Gonzalo Calvo, EACPT chair  
Filippo Drago, EPHAR chair  
Sandrine Salerno, Maire de Genève



**20:15 – 21:00**

**Welcome reception**

Exhibition and poster area



*Kindly offered by the Republic and Canton of Geneva and the City of Geneva*

# LOOKING FOR A PUBLISHING PARTNER?

## Visit us at the Elsevier Booth



Please attend our  
**Authors' Workshop:**  
**How to publish your paper  
in a scientific journal**

Moderator: **Dr. Richard Shader**,  
*Editor-in-Chief, Clinical Therapeutics*

Room 5 & 6

Thursday 29 August 2013 - 08:00 – 09:00

**Clinical Therapeutics** is dedicated to the dissemination of reliable and evolving evidence derived from clinical pharmacology and other therapeutic approaches to an international audience of scientists and clinicians working in a variety of research, academic, and clinical practice settings.



Clinical Therapeutics is the official journal  
of the European Association for Clinical  
Pharmacology and Therapeutics

Publish your article **Open Access**  
in **Clinical Therapeutics**



# THURSDAY 29 AUGUST 2013



08:00 – 09:00



Room 5-6

## Author's Workshop How to publish your paper in a scientific journal

*Chairperson:*  
Richard Shader, Editor-in-chief,  
Clinical Therapeutics



09:00 – 10:30



Room 2

## Personalizing cancer therapy

(Session co-organized with the  
American Society of Clinical  
Pharmacology and Therapeutics  
ASCPT)

*Chairpersons:*  
Caroline Samer, Matthias Schwab

**09:00** The individualisation of cancer therapy  
in organ dysfunction  
Michelle Rudek

**09:30** Targeted therapies in hematological  
malignancies  
Raymond Hohl

**10:00** Personalized therapy in breast cancer  
Matthias Schwab



Room 3

## New developments in TDM

*Chairpersons:*  
Thierry Buclin, Ylva Böttiger

**09:00** Monitoring drug therapy:  
TDM-te deum or tedium?  
Jeffrey Aronson

**09:30** Strategies for the development of TDM  
for targeted anticancer agents  
Thierry Buclin

**10:00** A simplified method for busulfan  
therapeutic drug monitoring using dried  
blood spot sampling in pediatric patient  
undergoing stem cell transplantation  
Chakradhara Rao Uppugunduri

**10:15** Clinical usefulness of therapeutic  
concentration monitoring for imatinib  
dosage individualization: results from  
the randomized controlled i-come trial  
Verena Gotta



Room 4

## Pharmacovigilance networks

(Sponsored by WHO)

*Chairpersons:*  
Lembit Rago, Shanthi Pal

**09:00** ENCEPP: Strengthening methodology,  
transparency and independence  
Henry Fitt

**09:30** WHO Programme for International Drug  
Monitoring  
Shanthi Pal

**10:00** What is the additional value of electronic  
medical records for drug safety signal  
detection? The experience of EU-ADR  
project  
Gianluca Trifiro



COFFEE BREAK  
10:30 – 11:00



**11:00 – 12:00**

Room 2

## Plenary: Anti-Angiogenic Therapy: New Insights

**Napoleone Ferrara**

*Chairperson:*  
Gonzalo Calvo

## EACPT Scientific and Special Awards (from 11:45)

**David Devos, Michael Orme**



**LUNCH & POSTERS GUIDED TOUR**  
12:00 – 13:30

**12:00 – 13:30**

Room 3

## Innovative Medicines Initiative

(Sponsored by IMI)

*Chairpersons:*  
Elisabetta Vaudano, Adam Vas

**12:00**

**IMI: A Public Private Partnership approach to the boosting of pharmaceutical R&D**  
Elisabetta Vaudano

**12:15**

**Creating new models for R&D in areas of unmet clinical need: Autism Spectrum Disorder**  
Will Spooren, Roche

**12:40**

**Addressing the challenges of diabetes and its complication: The IMI Diabetes Platform**  
Bernd Jablonka, Sanofi

**13:05**

**A PPP approach to boost antimicrobial resistance R&D: the ND4BB IMI platform**  
Seamus O'Brien, Astra Zeneca

**13:30 – 15:00**

Room 2

## Clinical trials regulation, control, benefits

(with the help of the Spanish Society of Clinical Pharmacology)

*Chairpersons:*  
Emilie Alirol, Gonzalo Calvo

**13:30**

**Introductory remarks to the revision of the EU Clinical Trials regulation**  
Gonzalo Calvo

**13:45**

**The clinical researcher view: Ideas for improvement**  
Cristina Avendaño

**14:30**

**Clinical and non-interventional trials assessment in Croatia**  
Dinko Vitezic

**14:45**

**The number of included older people in recent pre-authorisation trials**  
Erna Beers



Room 3

## Inflammatory disease and Biotherapeutics

*Chairpersons:*  
Francois Curtin, Edoardo Spina

**13:30**

**New targets in the treatment of rheumatoid arthritis**  
Zoltán Szekanecz

**14:00**

**Multiple Sclerosis - New chances ?**  
François Curtin

**14:30**

**Up-titration study with ponesimod, a selective s1p1 receptor modulator, to assess its maximum tolerated dose in healthy subjects**  
Matthias Hoch

**14:45**

**Off-label use and adverse events of biologic agents in paediatric patients with juvenile idiopathic arthritis**  
Julie Broe



Room 4

## Drug Safety: from clinical trials to clinical practice

(Sponsored by WHO)

Chairpersons:

Lembit Rägo, Shanti Pal

**13:30****CIOMS-From clinical trials to clinical practice-recent development**  
Gunilla Sjölin-Forsberg**14:00****The New Zealand centre for adverse drug reactions monitoring: a source of practice-based evidence**  
Ruth Savage**14:30****Regulatory decisions and drug safety – views from an agency outside EU**  
Rudolf Stoller**COFFEE BREAK**  
15:00 – 15:30**15:30 – 17:00**

Room 2

## Frontiers in Pharmacology

(Sponsored by BPS)

Chairpersons:

Mounir Pirmohamed, Mark Caulfield

**15:30****Novel clinical trial designs for assessing the efficacy of drugs**  
Max Parmar**16:00****Novel biomarkers of drug-induced liver injury**  
Kevin Park**16:30****Advances in genomics of blood pressure - time for translation**  
Mark Caulfield

Room 3

## Ocular Pharmacology

Chairpersons:

Edoardo Baglivo, Zoltan Szekanecz

**15:30****Anti-TNF in ocular diseases**  
Ildiko Süveges**16:00****Non infectious intermediate and posterior uveitis: treatment and place of local corticosteroids**  
Massimo Accorinti**16:30****Interferon alpha and posterior uveitis**  
Christine Fardeau**16:45****Sjögren ocular disease treatment**  
László Modis

Room 4

## Drug Safety in emerging countries

(Sponsored by WHO)

Chairpersons:

Lembit Rägo, Shanthi Pal

**15:30****Drug safety in emerging countries - a perspective from Nigeria**  
Ambrose Isah**16:00****Latin-American pharmacovigilance update report: a quick overview**  
Mariano Madurga Sanz**16:30****Overview of pharmacovigilance in resource limited settings: challenges and opportunities**  
Sten Olsson**BREAK**

17:00 – 17:30

**16:00 – 19:00**

Room 5-6

## EACPT Council Meeting

Private meeting



17:30 – 19:00



Room 2

## Pharmacology of Chocolate

*Chairperson:*  
Jules Desmeules

17:30

### Chocolate: pleasure for health

Claude Pichard  
Jeremy Ramsauer



Room 3

## The dopamine D3 receptor as a potential target for psychiatric diseases

(sponsored by Gedeon Richter)

*Chairpersons:*  
Gerhard Gründer, Adam Vas

17:30

### Antagonists and partial agonists at D2 and D3 dopamine receptors in psychiatric disorders: the spectrum of therapeutic options

Gerhard Gründer

17:50

### The functional role of D2 versus D3 dopamine receptors in health and disease

Peter Gmeiner

18:10

### Imaging the dopamine D2 and dopamine D3 receptors in the living brain

Ilan Rabiner

18:30

### A D3/D2 partial agonist antipsychotic with preferential D3 binding on the horizon

István Laszlovszky

18:50

### Concluding remarks

Gerhard Gründer



Room 13

## SSPM general assembly

Private meeting



19:00 – 21:00



## Chocolate tasting and cultural event

Exhibition and poster area

With the participation of

- Stettler  
[www.chocolaterie-stettler.ch](http://www.chocolaterie-stettler.ch)
- Merigonde  
[www.chocolaterie-merigonde.ch](http://www.chocolaterie-merigonde.ch)
- Paganel  
[www.paganel.ch](http://www.paganel.ch)
- Cartier  
[www.cartier-swiss.ch](http://www.cartier-swiss.ch)

Entertainment by Hornroh



# FRIDAY 30 AUGUST 2013

**09:00 – 10:30**

Room 2

## Diabetes

Chairpersons:

Markus Hodel, Matthias Schwab

**09:00** Novel antidiabetics: should they be used at all - and in whom?  
Christoph Meier

**09:30** Diabetes, diabetes risk factors and treatments, and breast cancer  
Peter Boyle

**10:00** Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes?  
Grigory Sidorenko

**10:15** Addressing the challenges of diabetes and its complication: the IMI diabetes platform  
Bernd Jablonka



Room 3

## PK/PD modelling

Chairpersons:

Chantal Csajka, Kim Brøsen

**09:00** The role of modelling and simulation in clinical pharmacology  
Kayode Ogungbenro

**09:30** Quantifying the impact of nevirapine based prophylaxis strategies to prevent mother-to-child transmission of HIV-1 using the population approach  
Charlotte Kloft

**10:00** Intrapulmonary pharmacokinetics and the intracellular disposition to support the long-lasting efficacy after an inhaled administration of its prodrug laninamivir octanoate  
Kaoru Toyama

**10:15** Optimal sampling strategy for busulfan in stem cell transplantation patients  
Francine Castro



Room 4

## Who should initiate drug development?

Chairpersons:

Oliver Hartley, Adam Vas

**09:00** Industry is more fit for clinical trials than academy  
Adam Vas

**09:30** Academia isn't so bad either  
Nicholas Moore

**10:00** Clinical trials registry and good clinical practice: an indian scenario  
Bikash Medhi

**10:15** Interchangeability of gabapentin generic formulations in The Netherlands: a comparative bioavailability study  
Marc Maliepaard



COFFEE BREAK

10:30 – 11:00

**11:00 – 12:00**

## Plenary: Immune mechanisms and atherosclerosis

Ziad Mallat

Chairperson: Hugo Kupferschmidt

## EACPT Lifetime Achievement Awards (from 11:45)

Sir Michael Rawlins, Carlo Patrono



LUNCH &amp; POSTERS GUIDED TOUR

12:00 – 13:30

**13:30 – 15:00**

Room 2

## Special cardiovascular pharmacology

*Chairpersons:**Jean-Luc Reny, Tabassome Simon*

**13:30** Clinical drug development of new anticoagulants: a lesson of modern clinical pharmacology  
Patrick Mismetti

**14:00** Novel approaches in the treatment of dyslipidaemias  
Anton F Stalenhoef

**14:30** Reversal strategy in antagonizing the P2Y12-inhibitor ticagrelor  
Eva-Luise Hobl

**14:45** Impact of circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction  
Tabassome Simon



Room 3

## Ethics

*Chairpersons:**Ingolf Cascorbi, Philippe Ducor*

**13:30** Ethics and Privacy of Biobanks  
Berenice Elger

**14:00** Public health genomics and personalized healthcare  
Angela Brand



Room 4

## Special liver pharmacology

*Chairpersons:**Gerd Kullak, Kari Kivisto*

**13:30** Immunological aspects of drug hypersensitivity – from molecule to man  
Kevin Park

**14:00** Acetaminophen-induced liver injury in experimental animals and humans  
Hartmut Jaeschke

**14:30** Assessment of drug-induced liver injury from clinical trial data  
Michael Merz



COFFEE BREAK  
15:00 – 15:30

**15:30 – 17:00**

Room 2

## Drug-drug Interactions

*Chairpersons:**Youssef Daali, Kim Brøsen*

**15:30** Complexity of predicting the magnitude of drug-drug interactions in an individual patient: this cannot fit to a pocket guide; iPad may be!  
Amin Rostami-Hodjegan

**16:00** Role of membrane transporters in drug interactions  
Mikko Niemi

**16:30** Interaction between mycophenolate mophetil and tacrolimus in kidney graft recipients  
Jan Strojil

**16:45** Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite in healthy volunteers  
Anne M Filppula



Room 3

## Advances in the treatment of rare diseases: Expectations on advanced therapies

*Chairpersons:**Ilse Kern, Gonzalo Calvo*

**15:30** New developments in the treatment of Inborn Errors of Metabolism  
Matthias Baumgartner

**16:00** Treating rare inborn errors of metabolism: from theory to practice  
Matthias Gautschi

**16:30** Gene therapy approval process at EMA  
Sol Ruiz

## **New targets for pain treatment**

Room 4

*Chairpersons:*  
Jules Desmeules, Dinko Vitezic

**15:30** Targets for drug development in HIV neuropathy  
Andrew Rice

**16:00** Transient receptor potential channels as novel drug targets  
Pierangelo Geppetti

**16:30** Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized double-blind placebo-controlled trial  
Alain Matthey

**16:45** A new pharmaceutical form of paracetamol : efficacy of transmucous buccal paracetamol in acute pain patients  
Gisele Pickering

*BREAK*  
17:00 – 17:30

## **EACPT Executive committee meeting**

Room 5-6

*Private meeting*



**17:30 – 19:00**



Room 2

## **Future Challenges for Clinical Pharmacology in Health Care**

(Sponsored by WHO)

*Chairpersons:*  
Lembit Rago, Folke Sjöqvist

**17:30** The background to the new WHO/ IUPHAR/CIOMS manifesto entitled "Clinical Pharmacology in Health Care, Teaching and Research" and the importance of the focus on health care  
Folke Sjöqvist

**18:00** Historical development and current state of Clinical Pharmacology in Russia  
Ksenia Zagorodnikova

**18:30** Clinical Pharmacology in Healthcare in Croatia  
Vera Vlahovic-Palcevsk



Room 3

## **Methodological issues in clinical trials with CNS drugs**

(Sponsored by Italian Society of Pharmacology)

*Chairpersons:*  
Pier Luigi Canonico, Edoardo Spina

**17:30** Clinical trials in epilepsy  
Emilio Perucca

**18:00** Clinical trials in neuropathic pain  
Soren Sindrup

**18:30** Clinical trials in schizophrenia  
Wolfgang Fleischacker



**20:00 – 23:00**

*GALA DINNER*



*Bateau "Le Lausanne"*  
Embarcadère des Pâquis, Quai du Mont-Blanc  
(Front of the Beau-Rivage Hotel)

**Tickets must be paid separately – see page 9 for more details**

# SATURDAY 31 AUGUST 2013



09:00 – 10:30



Room 2

## Best abstract, oral communications

*Chairpersons:*

*Pierre Dayer, Gonzalo Calvo*

- 09:00** Generic substitution of antiepileptic drug (AED) and loss of seizure control: a population-based case-crossover study  
Elisabeth Polard
- 09:15** Parenteral Busulfan in Myeloablative conditioning regimens for hematopoietic stem-cell transplantation (HSCT) in children  
Daniela Janeckova
- 09:30** Cedia assays for buprenorphine, methadone and EDDP in urine – simple methods, but sufficient for the purpose?  
Jon Berg
- 09:45** Target gene evaluation of two miRNAs differently expressed in focal and non-focal brain tissue of therapy-resistant epilepsy patients  
Sierk Haenisch
- 10:00** Self-empowering patients – a promising example in oral anticoagulation  
Stefan Vormfelde
- 10:15** Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment  
Victoria Rollason



Room 3

## Doping: Sports and Pharmacologists

*Chairpersons:*

*Mitsuko Kondo, Martial Saugy*

- 09:00** Development of partnerships between the biopharmaceutical industry and the world anti-doping agency  
Olivier Rabin
- 09:30** Doping in sport: The biomarkers are the best tools to measure its prevalence and to establish the individual monitoring of the athletes  
Martial Saugy
- 10:00** The makings of the world-class athlete: physiologic, genetic, psychosocial and economic determinants  
Yannis Pitsiladis



Room 4

## Neuro-Psychopharmacology: filling the gaps

*Chairpersons:*

*Marie Besson, Edoardo Spina*

- 09:00** Prediction of pharmacological effects of CNS-active agents during early phases of drug development  
Joop Van Gerven
- 09:30** New strategies in the treatment of major depression  
Francesc Artigas
- 10:00** Sleep quality of chronic benzodiazepine users in nursing homes: a comparative study with non-users  
Jolyce Bourgeois
- 10:15** Indications and dosages of atypical antipsychotics in Belgian nursing homes  
Majda Azermi



COFFEE BREAK AND POSTERS GUIDED TOUR  
10:30 – 11:15



11:15 – 12:00

CLOSING  
CEREMONY

AND POSTER  
AWARDS

## POSTER GUIDED TOUR

# WEDNESDAY 28 AUGUST 2013

⌚ 12:30 – 13:30

### PP001

#### ADHERENCE AND SELF-REPORTED MEDICATION-RELATED MORBIDITY: A POPULATION-BASED STUDY

K. Hedna\* (SE) - S. Hägg - K. Andersson Sundell - M. Petzold - K. Hakkarainen

### PP002

#### SEARCHING FOR HEALTH AND MEDICATION INFORMATION ON THE INTERNET. A REVIEW OF THE LITERATURE

A. Jesaimini\* (CH) - V. Rollason - C. Cedrashy - C. Luthy - M. Besson - C. Boyer - J. A. Desmeules - V. Piguet

### PP004

#### INCOMPLETE GENERIC SUBSTITUTION, PATIENT CO-PAYMENT AND ADHERENCE TO SSRIS IN ESTONIA

L. Rootslane\* (EE) - O. Laius

### PP005

#### RISK PERCEPTION AND COMPLIANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS

K. Burdová\* (CZ) - D. Friedecký - E. Faber - J. Strojil

### PP006

#### CLINICAL DISINTEGRATION TIME AND VOLUME OF WATER REQUIRED FOR ORALLY DISINTEGRATING TABLETS IN HEALTHY VOLUNTEERS

S. Uchida\* (JP) - T. Yoshita - S. Yagi - S. Hirata - T. Murao - S. Tanaka - N. Namiki

### PP008

#### DRUG-RELATED PROBLEMS IN A GENERAL INTERNAL MEDICINE SERVICE

B. Guignard\* (CH) - C. Samer - A. Perrier - P. Bonnabry - P. Dayer - J. Desmeules

### PP009

#### DEVELOPMENT, VALIDATION AND USABILITY OF SOFTWARE TO CALCULATE THE DRUG BURDEN INDEX: A PILOT STUDY

L. Kouladjian\* (AU) - D. Gnjdic - T. Chen - S. Hilmer

### PP010

#### MEDICATION SELF-ADMINISTRATION IN HOSPITALISED PATIENTS: AN EVALUATION USING DATA FROM AN ELECTRONIC PRESCRIBING AND MEDICATION ADMINISTRATION SYSTEM

S. J. Richardson - S. K. Thomas - S. E. McDowell - J. Hodson - M. Afzal - U. Nwulu - J. J. Coleman\* (GB)

### PP011

#### TIMELINESS OF MEDICINES ADMINISTRATION: USING DATA FROM AN ELECTRONIC PRESCRIBING SYSTEM TO MONITOR THE QUALITY OF MEDICINES PROVISION

S. K. Thomas\* (GB) - I. Clark - L. Denner - J. J. Coleman and Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme.

### PP012

#### NOT-IN-TRIAL SIMULATIONS: PREDICTING CARDIOVASCULAR RISK FROM CLINICAL TRIALS TO REAL LIFE CONDITIONS

O. Della Pasqua\* (GB) - A. Chain - J. Dieleman - C. van Noord - A. Hofman - B. Stricker - M. Sturkenboom - M. Danhof

### PP014

#### PHARMACOLOGICAL INTERVENTIONS: A WAY TO IMPROVE THE QUALITY OF ANTIBIOTIC USE

P. Mas-Morey\* (ES) - E. Sanmartin-Mestre - A. Ballesteros-Fernández - J. M. Bonell-Goytisolo - E. Alcoceba-Cruixent - C. Fuentes-Nieto

### PP015

#### CHRONOTHERAPY WITH DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL (5-FU) IN PATIENTS WITH ORAL SQUAMOUS CELL CARCINOMA

Y. Ioka\* (JP) - K. Ushijima - T. Ioka - T. Noguchi - Y. Jimbu - M. Kusama - A. Fujimura

### PP016

#### EXPOSURE TO ANTIPSYCHOTICS WITH PRO-ARRHYTHMIC RISK: COMBINING ADVERSE DRUG REACTIONS WITH DRUG UTILIZATION DATA

E. Raschi - E. Poluzzi - B. Godman\* (GB) - A. Koci - I. Bishop - M. Kalaba - O. Laius - U. Moretti - C. Sermet - M. Sturkenboom - F. De Ponti

### PP017

#### SPECTRUM OF OCULAR DIGOXIN TOXICITY IN THE ELDERLY: A CASE REPORT

D. Renard\* (CH) - E. Rubli - N. Voide - F.-X. Borruat - L. Rothuizen

► **PP018****STORAGE AND WASTAGE OF ANTIBACTERIAL AGENTS IN HOUSEHOLDS IN NOVI SAD, SERBIA**

M. Paut Kusturica\* (RS) - Z. Bukumiric - L. Ninkovic - Z. Tomic - A. Sabo

► **PP020****EFFECTS OF ARIPIPRAZOLE AND RISPERIDONE ON VENTRICULAR REPOLARIZATION IN CHILDREN AND ADOLESCENTS**

D. Italiano\* (IT) - C. Privitera - L. Guerriero - A. Gagliano - M. Lamberti - R. Siracusano - E. Germanò - M. P. Calabrò - E. Spina

► **PP022****VARIATIONS IN DRUG-INDUCED LIVER INJURY (DILI) BETWEEN DIFFERENT PROSPECTIVE DILI REGISTRIES**

I. Medina-Cáliz - A. González-Jiménez - F. Bessone - N. Hernández - A. Sánchez - M. Di Pace - M. Arrese - J. R. Brahm - A. Ruiz - J. Arancibia - D. Kershenobich - A. Loaeza - M. Giral - N. Mendez-Sanchez - M. Dávalos - M. Lizarzabal - E. Mengual - C. Stephens - M. Robles-Díaz - R. J. Andrade - M. I. Lucena\* (ES)

► **PP023****HEMODIALYSIS FOR CEFEPIME INTOXICATION: A CASE REPORT**

L.-Y. Mani - S. Kissling - M. Burnier - T. Buclin - D. Renard\* (CH)

► **PP024****ADVERSE DRUG EVENTS AND MEDICATION ERRORS RELATED TO PSYCHOTROPIC DRUGS IN PATIENTS PRESENTING AT AN EMERGENCY DEPARTMENT**

B. Pfistermeister\* (DE) - H. Dormann - A. Patapovas - F. Meier - F. Müller - A. Sonst - B. Plank-Kiegele - R. Vogler - O. Schöffski - T. Bürkle - R. Maas

► **PP025****IMPROVING HY'S LAW DEFINITION TO BETTER PREDICT THE RISK OF DEVELOPING ACUTE LIVER FAILURE IN DRUG-INDUCED LIVER INJURY (DILI)**

M. Robles-Díaz\* (ES) - C. Stephens - I. Medina-Cáliz - A. F. González - A. González-Jiménez - E. Ulzurrun - N. Kaplowitz - R. J. Andrade - M. I. Lucena

► **PP026****MEDIGENIA: INNOVATIVE CLOUD BASED SOLUTION FOR PHARMACOVIGILANCE**

S. Ussai\* (IT) - A. Giordano - G. Trillò - R. Petelin - G. Giagnorio

► **PP027****DRUG-INDUCED LIVER INJURY DETECTED THROUGH A PHARMACOVIGILANCE PROGRAM BASED IN LABORATORY SIGNALS**

H. Y. Tong\* (ES) - N. Medrano - C. Zegarra - A. Caparrós - A. Borobia - J. Frías - E. Ramírez

► **PP028****INFLUENCE OF PHARMACOLOGICAL EDUCATION ON AWARENESS OF THE RISK OF ADVERSE DRUG REACTIONS**

S. Mugosa\* (ME) - Z. Bukumiric - D. Protic - Z. Todorovic

► **PP029****PHARMACOVIGILANCE IN CRIMEA, UKRAINE IN 2012, ANNUAL REPORT**

O. V. Matvieiev\* (UA) - O. I. Koniaieva - N. V. Matvieieva - P. M. Radzivil

► **PP031****DRUG-ASSOCIATED ACUTE LIVER FAILURE LEADING TO REGISTRATION FOR TRANSPLANTATION IN FRANCE FROM THE STUDY OF ACUTE LIVER TRANSPLANT (SALT)**

E. Gulmez\* (FR) - D. Larrey - G.-P. Pageaux - J. Jové - R. Lassalle - S. Lignot - P. Blin - N. Moore

► **PP032****ANTIDEPRESSANT PRESCRIPTION BY GAUTENG DISPENSING DOCTORS**

S. Moch\* (ZA) - S. Laher-Sibda - J. Miot

► **PP033****EFFECTS OF PREGABALIN ON DRIVING**

M. Nomoto\* (JP) - T. Tsujii - W. T. Kyaw - N. Nishikawa - H. Iwaki - M. Nagai

► **PP036****HEPATOTOXICITY IN ACUTE AND REPEATED SUPRATHERAPEUTIC PARACETAMOL INGESTION IN CHILDREN AND ADOLESCENTS. RETROSPECTIVE COHORT STUDY CONDUCTED BETWEEN 2005 AND 2010**

H. Y. Tong\* (ES) - C. Zegarra - N. Medrano - A. Borobia - A. Carcas - J. Frías - E. Ramirez

► **PP037****INJECTION OF PHARMACEUTICAL TABLETS OF BUPRENORPHINE: DIFFERENCES BETWEEN SUBUTEX® AND ITS GENERICS**

R. Bouquié\* (FR) - C. Victorri-Vigneau - J. Clouet - G. Deslandes - P. Jolliet-Evin

► **PP038****SOY DIET CAUSES HISTOLOGICAL CHANGES ON THE REPRODUCTIVE ORGANS OF ADULT MALE RATS**

P. Papaioannidou\* (GR) - T. Papamitsou - I. Kyriakidis - I. Makaronidis - I. Papaioannidis - N. Papadimitriou - M. Dermentzopoulou

► **PP039****DIFFICULTIES IN PHARMACOVIGILANCE PRACTICES IN EUROPEAN NON-EU COUNTRIES AND THEIR DIFFERENCES FROM EU REQUIREMENTS**

J. Vukovic\* (RS) - N. Panjeskovic - O. Kypraios

► **PP040****DRUG INFORMATION UNIT – VALUABLE SOURCE OF INFORMATION, NOVI SAD EXPERIENCE**

S. Vukmirovic\* (RS) – A. Sabo – Z. Tomic – V. Vasovic – N. Stilinovic – A. Raskovic – B. Miliasevic – O. Horvat

► **PP042****SAFETY ASSESSMENT OF LOW DOSES OF METHADONE IN COMBINATION WITH BENZODIAZEPINES IN REAL OCCASIONS DURING METHADONE MAINTENANCE TREATMENT – A PILOT STUDY**

V. Mijatović\* (RS) – A. Dickov – S. Petković – T. Popov – I. Samojlik

► **PP043****THE INFLUENCE OF HE EDUCATIONAL AND ADMINISTRATIVE MEASURES ON THE TREND OF USE OF UTEROTONICS**

O. Horvat\* (RS) – N. Zeljkovic – M. Paut Kusturica – M. Ban – A. Sabo

► **PP044****TOXICOLIST – A WEB-SERVICE TO IMPROVE PATIENT-SAFETY**

J. Ahlner\* (SE) – H. Druid

► **PP045****THE EFFECTS OF YARROW'S (ACHILLEA MILLEFOLIUM) HYDRO ALCOHOLIC EXTRACT ON BLOOD PROTEINS IN MICE**

M. Modaresi\* (IR) – D. Dadkhah

► **PP046****MEDICATION SELF-ADMINISTRATION IN HOSPITALISED PATIENTS: AN EVALUATION USING DATA FROM AN ELECTRONIC PRESCRIBING AND MEDICATION ADMINISTRATION SYSTEM**

S. J. Richardson – S. K. Thomas – S. E. McDowell – J. Hodson – M. Afzal – J. J. Coleman\* (GB)

► **PP047****DO JUNIOR DOCTORS HAVE ENOUGH READY KNOWLEDGE OF THE DRUGS THEY PRESCRIBE?**

B. H.-E. Jansen\* (NL) – G. W. Disselhorst – D. Brinkman – J. Tichelaar – M. Richir – R. Unen, van – T. Vries, de

► **PP048****A SYSTEMATIC REVIEW ON LEARNING IN A STUDENT RUN CLINIC**

T. Schutte\* (NL) – J. Tichelaar – R. S. Dekker – M. A. van Agtmael – M. C. Richir – T. P. G. M. de Vries

► **PP050****SALIVA-BASED CYP1A2 PHENOTYPING USING CAFFEINE FROM BEVERAGES: A PRACTICAL COURSE FOR STUDENTS**

A. Jetter\* (CH) – J. Mwingi – C. Schaffner – G. A. Kullak-Ublick

► **PP053****CHALLENGES IN UNDERGRADUATE PHARMACOTHERAPY EDUCATION: THE GHENT UNIVERSITY EXPERIENCE**

L. M. Van Bortel\* (BE) and Pharmacotherapy Task Force

► **PP054****PRESCRIBING COMPETENCE IN RELATION TO CONCEPTUAL AND CONTEXTUAL TEACHING AND LEARNING**

S. Moch\* (ZA)

► **PP055****PERSISTENT FEVER IN A WOMAN FOLLOWING RIGHT KNEE HEMIARTHROPLASTY**

P. C. Eng\* (GB) – D. Dworakowska

► **P057****THE OPERATIONALIZATION OF ELECTRONIC INN PRESCRIBING**

E. Van Bever\* (BE) – V. J. Wirtz – M. Azermi – G. De Loof – T. Christiaens – L. Nicolas – L. Van Bortel – R. Vander Stichele

► **PP058****NEW MEDICINES AND DEVELOPMENT STRATEGIES NECESSITATES CHANGE IN LIFELONG EDUCATION OF CLINICAL PHARMACOLOGY**

S. – Kerpel-Fronius\* (HU)

► **PP060****PATENTED DRUG EXTENSION STRATEGIES AND HOSPITAL RESTRICTIVE DRUG FORMULARY: A COST-EVALUATION ANALYSIS**

N. Vernaz\* (CH) – G. Haller – F. Girardin – B. Huttner – C. Combescure – P. Dayer – D. Musciconico – J.-L. Salomon – P. Bonnabry

► **PP061****RECENT REFORMS IN SCOTLAND TO TAKE ADVANTAGE OF GENERICS, THEIR INFLUENCE AND IMPLICATIONS FOR HEALTH AUTHORITIES CONTEMPLATING FUTURE REFORMS**

B. Godman\* (GB) – I. Bishop – S. Campbell – J. Miranda – M. Bennie

► **PP062****VARIABLE APPROACHES IN EUROPE TO THE AVAILABILITY OF GENERIC LOSARTAN; IMPLICATIONS FOR THE FUTURE**

B. Godman\* (SE) – M. Bennie – A. Bucsecs – U. Hesse – A. Martin – J. Miranda – S. Simoens – C. Zara – L. L. Gustafsson

► **PP063****CHANGES IN THE UTILISATION OF VENLAFAXINE AFTER THE INTRODUCTION OF GENERICS IN SWEDEN: IMPLICATIONS FOR OTHER COUNTRIES**

B. Godman\* (SE) – M. Persson – J. Miranda – B. Wettermark – C. Barbui – L. L. Gustafsson

► **PP064**

**AGRANULOCYTOSIS DETECTION OUTCOME BY CLOZAPINE TREATMENT (ADOC STUDY) IN PSYCHIATRY: A COST-EFFECTIVENESS STUDY**

F. R. Girardin\* (CH) - A. Poncet - M. Blondon - V. Rollason - N. Vernaz - P. Dayer - C. Combescure

► **PP065**

**AN INVESTIGATION OF THE HORIZON SCANNING APPROACH USED FOR NEW MEDICINES IN THE SCOTTISH NATIONAL HEALTH SERVICE**

M. Bennie - J. Dear - E. Dunlop Corcoran - S. Hems\* (GB) - R. Newham - S. McTaggart - C. Waugh

► **PP066**

**DO THE ANTIBIOTICS BOUGHT WITHOUT PRESCRIPTION INFLUENCES THE TOTAL AMOUNT OF ANTIBIOTICS?**

O. Horvat\* (RS) - V. Mijatovic - Z. Tomic - S. Vukmirovic - A. Sabo

► **PP068**

**A CROSS-SECTIONAL PILOT STUDY ASSESSING NEEDS FOR AND ATTITUDES TO IMPLEMENTATION OF INFORMATION AND COMMUNICATION TECHNOLOGY FOR RATIONAL USE OF MEDICINES AMONG HEALTHCARE STAFF IN RURAL TANZANIA**

J. Nilseng - L. L. Gustafsson - A. Nungu - P. Bastholm-Rahmner - D. Mazali - B. Pehrson - J. Eriksen\* (SE)

► **PP069**

**ABCD(2) RISK SCORING IS NOT AN EFFECTIVE TRIAGE TOOL FOR PREDICTING NEED FOR URGENT TREATMENT IN PATIENTS WITH SYMPTOMATIC CEREBRAL MICROEMBOLI OR CRITICAL CAROTID ARTERY STENOSIS**

M. Saedon - C. E. Hutcheson - C. Imray - D. R. J. Singer\* (GB) and Carotid Research Group

► **PP070**

**HOSPITAL INFECTIONS IN INTERNAL MEDICINE INTENSIVE CARE CLINIC: INCIDENCE, CAUSATIVE AGENTS AND ANTIMICROBIAL CONSUMPTION**

M. Miljkovic - N. Konstantinovic - A. Kovacevic\* (RS) - N. Rancic - V. Suljagic - B. Rakonjac - S. Vukotic - V. Dragojevic-Simic

► **PP072**

**URINARY TRACT INFECTIONS TREATMENT - PRESCRIBING PATTERNS, GUIDELINES, AND LOCAL RESISTANCE IN HEALTH CENTRE NOVI SAD**

S. Vukmirovic\* (RS) - O. Horvat - Z. Tomic - B. Milijasevic - A. Sabo

► **PP074**

**POTENTIAL EFFECT OF ALPHA-CHYMOTRYPCIN ON GROWTH FACTORS IN ALZHEIMER'S DISEASE MODEL**

A. B. Shalby\* (EG) - H. H. Ahmed - F. M. Metwally



## POSTER GUIDED TOUR

# THURSDAY 29 AUGUST 2013

12:30 – 13:30

► **PP077**  
**ENDOTHELIAL DYSFUNCTION DUE TO ISCHEMIA-REPERFUSION INJURY IS NOT PREVENTED BY METFORMIN THERAPY IN HEALTHY VOLUNTEERS**  
S. Elmessaoudi\* (NL) - T. Schreuder - R. Kengen - D. Thijssen - G. Rongen - N. Riksen

► **PP078**  
**COMPARISON OF A NEW ELISA-BASED WITH THE FLOW CYTOMETRIC ASSAY FOR VASODILATOR-ASSOCIATED STIMULATED PHOSPHOPROTEIN (VASP) PHOSPHORYLATION TO ASSESS P2Y12-INHIBITION AFTER TICAGRELOR INTAKE**  
E.-L. Hobl\* (AT) - B. Jilma - U. Derhaschnig - C. Schoergenhofer - M. Schwameis - P. Jilma-Stohlawetz

► **PP080**  
**THE ROLE OF THE KCNJ5 POTASSIUM CHANNEL VARIANTS IN ALDOSTERONE RELEASE**  
G. Massimo\* (GB) and M. Murthy, M. Stowasser, K. O'Shaughnessy

► **PP081**  
**EVALUATION OF HYPOGLYCEMIC ACTIVITY OF A NOVEL LONG ACTING INSULIN ANALOGUE**  
M. Pawłowska\* (PL) - M. Bogiel - K. Sitarek - J. Gromadzińska - M. Bujalska-Zadrożny - A. Heinze - P. Borowicz

► **PP082**  
**PRESCRIPTION OF RECOMMENDED DRUGS FOR ACUTE MYOCARDIAL INFARCTION IN ESTONIA IN 2001 VS 2007 AND IN 2007 VS 2011**  
T. Marandi\* (EE) - M. Blöndal - A. Tiia - J. Eha

► **PP083**  
**DABIGATRAN - DEMONSTRATES THE NEED FOR COMPREHENSIVE APPROACHES TO OPTIMISE THE USE OF NEW DRUGS**  
R. E. Malmstrom - B. Godman\* (SE) - E. Diogene - M. Bennie - J. Furst - I. Gutiérrez-Ibarluzea - L. McCullagh - V. Vlahovic-Palcevski - L. L. Gustafsson

► **PP084**  
**A EUROPEAN SCORE PREDICTS BETTER SOUTH AMERICAN CARDIOVASCULAR RISK THAN FRAMINGHAM RISK EQUATIONS**  
I. Marchant\* (CL) - F. Gueyffier

► **PP086**  
**USAGE OF ANTIHYPERTENSIVE DRUGS IN SERBIA: AGE AND GENDER STRATIFICATION**  
A. Tomas\* (RS) - O. Horvat - Z. Tomic - M. Ban - A. Sabo

► **PP088**  
**NITROSONIFEDIPINE, A PHOTODEGRADATION PRODUCT OF NIFEDIPINE, SUPPRESS THE PROGRESSION OF DIABETIC NEPHROPATHY WITH THE ENDOTHELIAL DYSFUNCTION**  
T. Sakurada\* (JP) - K. Miyako - Y. Horinouchi - K. Teraoka - T. Kujime - K. Kawazoe - H. Houchi - T. Tamaki - K. Minakuchi

► **PP090**  
**THE 3.5-YEAR MORTALITY IMPACT OF DRUGS IN SECONDARY PREVENTION OF MYOCARDIAL INFARCTION IN REAL-LIFE (INTERIM ANALYSIS OF THE EOLE COHORT)**  
C. Droz - C. Dureau - D. Thomas - N. Danchin - J. Tricoire - J. Bénichou - F. Paillard - S. Herberg - I. Sibon - F. Rouanet - S. Rambelomanana - H. Maïzi - M.-A. Bernard - P. Blin - N. Moore\* (FR)

► **PP091**  
**COMPLEX REGULATION OF ALPHA-ADRENOCEPTOR-MEDIATED VASOCONSTRICTION IN HUMAN INTERNAL THORACIC ARTERIES**  
L. E. Wilkins\* (GB) - J. Watkins - A. Marsh - D. R. J. Singer and Personalised Medicines Group

► **PP092**  
**CHANGES IN VASCULAR REACTIVITY CAUSED BY ANGIOTENSIN II IN ISOLATED VESSELS OF RAT AORTA IN A MODEL OF HYPERTENSION**  
E. M. Lopez-Calderon\* (MX) - L. N. Acevedo-Villavicencio - G. C. Villanueva-Lopez - E. Lara-Padilla - G. Guevara-Balcazar - E. Hong-Chong - M. C. Castillo-Hernandez

► **PP094**  
**TARGETS OF THERAPY OF PATIENTS WITH CONGESTIVE HEART FAILURE CAUSED BY ISCHEMIC HEART DISEASE AND DIABETES**  
I. I. Megreladze - N. V. Gongadze\* (GE) - T. D. Kezeli - K. S. Kakabadze - M. G. Mirziashvili - Z. V. Chapichadze - G. V. Sukoyan

► **PP098****NICORANDIL INDUCED ENDOTHELIUM-INDEPENDENT RELAXATION OF ARTERIAL BYPASS GRAFT**

M. Marinko\* (RS) - A. Novakovic - I. Stojanovic - P. Milojevic - M. Jovic - D. Nenezic - N. Ugresic - V. Kanjuh - Q. Yang - G.-W. He

► **PP100****POTENTIAL OF NATTOKINASE AS AN ANTITHROMBOTIC & FIBRINOLYTIC AGENT**

T. Shirole\* (IN) - S. L. Sharma - A. G. Jagtap

► **PP101****REACTIVITY MODIFICATIONS IN HEART RESISTANCE VESSELS TO ANGIOTENSIN II IN ISOLATED PERFUSED HEART OF HYPERTENSIVE RATS**

M. Lopez-Calderon\* (MX) - L. N. Acevedo-Villavicencio - G. C. Villanueva-Lopez - E. Lara-Padilla - G. Guevara-Balcazar - E. Hong-Chong - M. C. Castillo-Hernandez

► **PP102****MOLECULAR DOCKING RESEARCH & IN-VITRO ANALYSIS OF NOVEL NATURAL AND SYNTHETIC PTP 1B INHIBITORS AS POTENTIAL THERAPEUTIC TARGET FOR DIABETES MELLITUS**

D. Ahmed\* (IN)

► **PP103****EFFECTS OF CLOFIBRATE ON OUABAIN-INDUCED ARRHYTHMIA IN ISOLATED RAT ATRIA**

A. Bakhtiaran - S. Moradi\* (IR) - V. Nikoui - F. Jazayeri

► **PP105****THE ROLE OF POLY (ADP-RIBOSE) POLYMERASE (PARP) PATHWAY ON ENDOTHELIN-1 (ET-1)-INDUCED ENDOTHELIAL DYSFUNCTION IN RAT THORACIC AORTA**

B. Yilmaz - P. Sahin - E. Ordueri - C. Celik-Ozenci - A. Tasatargil\* (TR)

► **PP106****PREDICTORS FOR THE IMPROVEMENT OF LEFT VENTRICULAR EJECTION FRACTION IN DILATED CARDIOMYOPATHY: RESULTS FROM A COHORT FROM THE CLINICAL COUNTY HOSPITAL CLUJ-NAPOCA**

C. Pop\* (RO) - E. Buzdugan - F. Loghin - C. Mogosan

► **PP107****CHRONIC TREATMENT WITH TAURINE AMELIORATES DIABETES-INDUCED DYSFUNCTION OF NITRIC OXIDE-MEDIATED NEUROGENIC AND ENDOTHELIUM-DEPENDENT CORPUS CAVERNOSUM RELAXATION IN RATS**

S. Dalaklioglu\* (TR) - N. Kescu - C. Celik-Ozenci - Z. Bayram - C. Nacitarhan - S. S. Ozdem

► **PP114****SUNITINIB DOES NOT REDUCE ENDO-THELIUM-DEPENDENT VASODILATION IN HUMANS**

A. Thijs\* (NL) - W. T. van der Graaf - C. M. van Herpen - G. A. Rongen

► **PP115****LOSS OF NFκB ACTIVITY DECREASES HEAT SHOCK PROTEIN LEVELS IN PANCREATIC CANCER CELLS**

U. Matsathit\* (TH) - O. McGinn - V. Sangwan - S. Banerjee - L. Phivthong-ngam - A. K. Saluja

► **PP116****METASTATIC BREAST CARCINOMA INDUCES VASCULAR ENDOTHELIAL DYSFUNCTION IN BALB-C MICE: ROLE OF TUMOR NECROSIS FACTOR-ALPHA AND NADPH-OXIDASE**

S. Dalaklioglu\* (TR) - A. Tasatargil - S. Kale - G. Tanriover - S. Dilmac - N. Erin

► **PP117****THE VARYING EFFECTS OF PENTOXIFYLLINE ON CYCLIN D1 LEVELS AND G1 PHASE ARREST IN DIFFERENT RENAL CELL CARCINOMA CELL MODELS**

N. Mastrandrea\* (US) - W. L. Cai - K. Y. Tham - T. J. Monks - S. S. Lau

► **PP118****IN VITRO STUDY OF SONODYNAMIC AND PHOTODYNAMIC TREATMENT ON HUMAN CANCER CELL LINES**

F. Foglietta\* (IT) - R. Canaparo - A. Francovich - P. Civera - L. Serpe

► **PP119****EFFECT OF LIPOSOMAL CURCUMIN ON RED BLOOD CELLS IN VITRO**

A. Storka\* (AT) - B. Vcelar - L. Helson - M. Wolzt

► **PP120****CHEMOTHERAPEUTIC ANTITUMOR ACTIVITIES OF CURCUMIN**

A. M. El-Medany\* (EG) - H. H. Hagar - O. A. Nayel - J. M. El-Medany

► **PP121****CYP2C9 GENOTYPES ASSOCIATED WITH HIGHER SULFOLANE LEVELS IN CHILDREN RECEIVING INTRAVENOUS BUSULFAN PRIOR TO HEMATOPOIETIC STEM CELL TRANSPLANTATION**

C. R. S. Uppugunduri\* (CH) - Y. Daali - M. A. Rezgui - P. Huez Diaz - A. K. Tyagi - J. Rousseau - M. Duval - H. Bittencourt - M. Krajcinovic - M. Ansari

► **PP122****REGULATION OF HUMAN LEUKOCYTE ANTIGEN EXPRESSION AND NEVIRAPINE-INDUCED ADVERSE DRUG REACTIONS IN A MALAWIAN HIV-POSITIVE POPULATION**

E. M. Cornejo Castro\* (GB) - D. F. Carr - V. A. Marshall - M. Chaponda - S. Lane - A. Alfrevic - D. Whitby - M. Carrington - M. Pirmohamed

► **PP124****PHARMACOKINETICS OF TOLPERISONE IN RELATION TO CYP2C19 GENOTYPES**

J.-Y. Byeon\* (KR) - J.-Y. LEE - J.-S. JEON - J.-E. Lee - S.-H. KIM - C.-G. JANG - S.-Y. LEE

► **PP126****IN-VITRO REACTIVITY OF DRUG-SPECIFIC T-CELLS FROM A HLA-A\*31:01 POSITIVE CARBAMAZEPINE HYPERSENSITIVE PATIENT**

M. Lichtenfels\* (GB) - D. J. Naisbitt - A. Alfrevic - K. B. Park - M. Pirmohamed

► **PP127****CYP4F2 AND APOE CONTRIBUTION IN ACENOCOUMAROL DOSING BASED ON GENOTYPE: A COMPARISON OF TWO ALGORITHMS**

H. Y. Tong\* (ES) - A. M. Borobia - R. Lubomirov - C. Zegarra - S. H. Lei - J. Frías - A. J. Carcas

► **PP128****IMPACT OF VARIABILITY IN THE BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) GENE IN EATING DISORDER PATIENTS**

C. Gamero - I. Flores - J. A. Carrillo - A. Garcia-Herraz - I. Gordillo - M. Monge - M. Jimenez - R. Rodriguez-Lopez - G. Gervasini\* (ES)

► **PP129****TIME-TO-ACHIEVE STABILITY OF ANTICOAGULATION IS DECREASED IN ABCB1 MUTATED PATIENTS TREATED WITH ACENOCOUMAROL**

V. Rollason\* (CH) - L. Gschwind - Y. Daali - F. Boehlen - M. Rebsamen - C. Combescure - A. Matthey - P. Bonnabry - P. Dayer - J. A. Desmeules

► **PP130****EVALUATION OF THE INFLUENCE OF CYTOCHROME P450 OXIDOREDUCTASE (POR) IN THE STABLE DOSE OF ACENOCOUMAROL**

A. M. Borobia - H. Y. Tong\* (ES) - R. Lubomirov - G. N. Almeida-Paulo - C. Zegarra - J. Frías - A. J. Carcas

► **PP131****INTERACTION BETWEEN POLYMORPHISMS IN OCT2 AND MATE1 AND METFORMIN RENAL CLEARANCE**

M. M. Hougaard Christensen\* (DK) - R. S. Pedersen - T. Bjerregaard Stage - C. Brasch-Andersen - F. Nielsen - P. Damkier - H. Beck-Nielsen - K. Brosen

► **PP132****CONTRIBUTION OF GENETIC (CYP3A5, ABCB1 AND POR) AND NON-GENETIC VARIABLES TO THE ORAL TACROLIMUS CLEARANCE IN CHILDREN'S WITH STABLE KIDNEY TRANSPLANT, DURING ADVAGRAF® TREATMENT**

G. N. Almeida-Paulo\* (ES) - R. Lubomirov - N. L. Alonso-Sanchez - L. Espinosa - A. J. Carcas

► **PP133****PHARMACOGENETICS OF THE HUMAN SEROTONIN TRANSPORTER**

K. Münch\* (DE) - J. Stump - H. Sticht - M. F. Fromm - O. Zolk

► **PP134****ESOMEPRAZOLE USED AS A BOOSTER IN A HIV ULTRARAPID CYP2C19 METABOLIZER TREATED WITH VORICONAZOLE**

Y. Bouatou\* (CH) - C. F. Samer - K. Ing Lorenzini - Y. Daali - S. Daou - M. Fathi - M. Rebsamen - J. Desmeules - A. Calmy - M. Escher

► **PP135****PHARMACOMETABOLOMICS FOR INDIVIDUALIZED TREATMENT OF ALCOHOLISM: HIGH SERUM GLUTAMATE LEVEL IS ASSOCIATED WITH POSITIVE RESPONSE TO ACAMPROSATE TREATMENT**

D.-S. Choi\* (US) - H. W. Nam - V. Karpyak

► **PP136****GENETIC POLYMORPHISM OF CYP2D6 SIGNIFICANTLY AFFECTS THE PHARMACOKINETICS OF TOLPERISONE**

J. Byeon\* (KR) - J.-Y. LEE - J.-S. JEON - J.-E. LEE - S. H. KIM - C.-I. CHOI - Y.-J. LEE - J.-W. BAE - C.-G. JANG - S.-Y. LEE

► **PP137****EFFECTS OF THE GENETIC POLYMORPHISMS OF HUMAN MULTIDRUG AND TOXIN EXTRUSION 1 (HIMATE1/SLC47A1) TRANSPORTER ON THE RENAL TUBULAR SECRETION OF N1-METHYLNICOTINAMIDE**

R. Ogawa\* (JP) - T. Mikami - M. Takahashi - H. Echizen

► **PP138****ANALYSIS OF CYP2D6 GENETIC POLYMORPHISMS IN MEXICAN MESTIZOS, LACANDONES AND TZELTALES**

M. Lopez Lopez - E. M. Peñas-Lledó - O. Alberto - P. Dorado - T. Corona - A. Ochoa Morales - P. Yescas - M. E. Alonso Vilatela - A. Llerena\* (ES)

► **PP139****ASSOCIATION OF ABCB1, ABCC2, CYP2C9 AND CYP2C19 POLYMORPHISM WITH PHENYTOIN PLASMA CONCENTRATIONS**

A. Ortega Vázquez - N. Monroy Jaramillo - P. Dorado - I. F. Galindo - I. E. Juárez Martínez - H. Jung Cook - E. M. Peñas-Lledó - A. Ochoa Morales - M. E. Alonso Vilatela - A. Llerena\* (ES) - M. Lopez Lopez

► **PP140**

THE CONTRIBUTION OF PLATELET GLYCOPROTEINS (GPIA C807T AND GPIBA C-5T) AND CYCLOOXYGENASE 2 (COX-2 G--765C) POLYMORPHISMS TO PLATELET RESPONSE IN PATIENTS TREATED WITH ASPIRIN

S. Al-Azzam\* (JO) - K. H. Alzoubi - O. Khabour - D. Tawalbeh - O. Al-Azzeh

► **PP141**

THE RELEVANCE OF PLATELET GLYCOPROTEIN GP IIB/IIIA POLYMORPHISM TO ANTI-PLATELETS RESPONSE IN ACUTE CORONARY SYNDROME[ACS]

O. A. Nayel\* (EG) - M. I. Sobhey - A. M. Baraka - M. A. H. Al Samak - S. I. Abdel Qauder

► **PP142**

INFLUENCE OF THE CYP2D6 -1584C>G PROMOTER POLYMORPHISM ON THE PHENOTYPE OF DEBRISOQUINE IN HEALTHY VOLUNTEERS FROM CUBA AND NICARAGUA

M. E. G. Naranjo\* (ES) - P. Dorado - L. R. Calzadilla - M. Álvarez - R. Ramírez - E. M. Peñas-Lledó - B. Pérez - I. González - A. Llerena and CEIBA Consortium.

► **PP143**

IMPACT OF UGT1A4 GENOTYPE IN THE CLINICAL RESPONSE TO LAMOTRIGINE IN PATIENTS WITH EPILEPSY

A. Ortega Vázquez - P. Dorado - S. Rojas Tomé - I. Iris Martínez Juárez - H. Jung Cook - N. Monroy Jaramillo - M. E. Alonso Vilatela - E. M. Peñas-Lledó - A. Llerena\* (ES) - M. Lopez Lopez

► **PP144**

ASSESSING IN VIVO ENZYME GENETIC VARIATION IN THE PRESENCE OF TRANSPORTER EFFECT

R. Chauhan\* (GB) - N. Tsamandouras - A. Rostami-Hodjegan

► **PP145**

DISTRIBUTION OF GENETIC VARIANTS OF CYP2D6 IN AMERINDIANS FROM NORTHWEST MEXICO

B. P. Lazalde-Ramos - C. Galaviz - M. Martínez-Fierro - I. Garza Veloz - M. E. G. Naranjo - M. G. Sosa-Macias - A. Llerena\* (ES)

► **PP146**

ABCB1 C3435T POLYMORPHISM IS ASSOCIATED WITH SUSCEPTIBILITY TO MAJOR DEPRESSION BUT NOT CLINICAL RESPONSE TO CITALOPRAM IN TURKISH POPULATION

G. Ozbey\* (TR) - B. Yucel - S. Erdogan Taycan - D. Kan - N. Eren Bodur - T. Arslan - N. Yuksel - F. Percin - I. C. Guzey - C. Uluoglu

► **PP147**

CYP2D6 GENETIC POLYMORPHISMS AMONG THREE COSTA RICAN POPULATIONS

C. Céspedes Garro\* (CR) - G. Jiménez-Arce - M. E. G. Naranjo - R. Barrantes - A. Llerena and CEIBA Consortium

► **PP148**

INFLUENCE OF CYP2C9 IVS8-109A>T POLYMORPHISM ON LOSARTAN OXIDATION IN HEALTHY ECUADORIANS

P. Dorado - A. Gallego - L. J. Beltrán - E. M. Peñas-Lledó - E. Terán - A. Llerena\* (ES)

► **PP149**

THE CEIBA COCKTAIL FOR DRUG HYDROXYLATION PHENOTYPING IN HISPANIC POPULATIONS

F. De Andres - M. E. G. Naranjo - M. Sosa-Macías - B. P. Lazalde Ramos - E. Tarazona-Santos - A. Llerena\* (ES) and CEIBA Consortium.

► **PP151**

PREVALENCE OF CARRIAGE CYP2C9, VKORC1 AND CYP4F2 POLYMORPHISMS IN RUSSIAN PATIENTS WITH HIGH THROMBOTIC RISK PRESCRIBED WARFARIN COMPARED WITH OTHER ETHNIC GROUPS

D. Ivashchenko\* (RU) - D. Sychev - I. Rusin - A. Grachev - T. Beloshickaya

► **PP152**

TENDENCY TO HIGHER ACTIVITY OF CYP3A5 IN WOMEN WITH STILLBIRTH

K. Zagorodnikova\* (RU) - M. Kondrahina - J. Rustanovich - D. Kostyuchek

► **PP153**

EVALUATION OF THE RELATIONSHIPS BETWEEN ABCB1 C3435T AND G2677T/A POLYMORPHISMS AND CLINICAL RESPONSE TO VENLAFAXINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

G. Ozbey\* (TR) - F. Cam Celikel - B. Elbozan Cumurcu - D. Kan - B. Yucel - E. Hasbek - F. Percin - C. Uluoglu

► **PP154**

PERSONALISING HEALTH CARE: FEASIBILITY AND FUTURE IMPLICATIONS FOR ALL STAKEHOLDER GROUPS INCLUDING AUTHORITIES, PHYSICIANS AND PATIENTS

B. Godman\* (SE) - A. E. Finlayson - P. Cheema - E. Zebedin-Brandl - I. Gutiérrez-Ibarluzea - E. Diogene - K. Paterson - V. Vlahovic-Palcevski - L. L. Gustafsson

► **PP155**

PREVALENCE OF GENE POLYMORPHISM SLCO1B1 IN PATIENTS WITH DYSLIPIDEMIA AND SYSTEMIC ATHEROSCLEROSIS IN RUSSIAN POPULATION

A. Sirotkina\* (RU) - A. Khokhlov - E. Voronina

► **PP156**

CYP2D6 GENOTYPES AND PREDICTION OF METABOLIC PROFILES IN THE PORTUGUESE POPULATION: CLINICAL IMPLICATIONS

J. Albuquerque - C. Ribeiro - M. E. G. Naranjo - A. Llerena - M. Grazina\* (PT) and CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF

■ **PP157**

**CYP2C9 ALLELE FREQUENCIES AMONG THREE COSTA RICAN ETHNIC GROUPS COMPARED TO HISPANIC POPULATIONS**

C. Céspedes-Garro\* (ES) - P. Dorado - G. Jiménez-Arce - M. E. G. Naranjo - R. Barrantes - A. LLerena and CEIBA Consortium


■ **PP159**

**C677T POLYMORPHISM OF METHYLENETETRA-HYDROFOLATE REDUCTASE AND HOMOCYSTEINE CONCENTRATION IN PATIENTS WITH ESSENTIAL HYPERTENSION**

N. B. Sidorenkova\* (RU) - N. Terentyeva - G. Kostychenko - M. Plyasheshnikov

➤ **POSTER GUIDED TOUR**

**FRIDAY  
30 AUGUST  
2013**

 12:30 – 13:30

■ **PP161**

**COMPARISON OF EFFECT OF RALOXIFENE ON THE COAGULATION AND FIBRINOLYTIC SYSTEMS BETWEEN MORNING AND EVENING DOSING REGIMENS IN POST-MENOPAUSAL WOMEN WITH OSTEOPOROSIS**

K. Ushijima\* (JP) - H. Ando - A. Fujimura

■ **PP162**

**THOROUGH QT STUDY WITH PONESIMOD, A SELECTIVE S1P1 RECEPTOR MODULATOR**

M. Hoch\* (CH) - A. Vaclavkova - R. Stoltz - P. Brossard - J. Dingemanse

■ **PP163**

**PBMC INCREASE SIRTUIN3 PROTEIN EXPRESSION IN ACUTE ADAPTATION TO HYPOXIA IN HUMANS**

A. Storka\* (AT) - L. Wang - G. Führlinger - M. Wolzt

■ **PP164**

**DIPYRIDAMOLE DOES NOT LIMIT MYOCARDIAL ISCHEMIA-REPERFUSION INJURY AFTER CORONARY ARTERY BYPASS GRAFTING REGARDLESS AMPD1 GENOTYPE**

S. El Messaoudi\* (NL) - C. Wouters - H. V. Swieten - P. Pickkers - E. Abbink-Zandbergen - A. Rasing-Hoogveld - M. Bouw - N. Riksen - G. Rongen

■ **PP165**

**EVALUATION OF JNJ-26489112, A NOVEL ANTIEPILEPTIC DRUG: A PLACEBO-CONTROLLED, EXPLORATORY STUDY**

D. Kasteleijn - Nolst Trenité\* (IT) - N. A. Diprospero - J. A. Moyer - J. Gambale - G. Pandina - L. Ford - S. Girgis - L. Xi - J. Nye

► **PP166**

EFFECT OF CARVEDILOL VERSUS CARVEDILOL/IVABRADINE COMBINATION ON HEART RATE, QUALITY OF LIFE, MORBIDITY AND MORTALITY IN PATIENTS WITH STABLE ISCHEMIC HEART FAILURE

T. Al Saadi\* (OM) - M. Sallam - K. Al Hashmi - A. M. Elhawary

► **PP167**

INTEGRATED 14C STUDY DESIGNS TO PROVIDE INTRAVENOUS PK AND HUMAN MASS BALANCE AND METABOLISM DATA FROM A SINGLE PROTOCOL AND A SINGLE REGULATORY SUBMISSION

L. Stevens\* (GB) - I. Shaw

► **PP168**

A SURVEY ON A CLINICAL RESEARCH INFORMATION PORTAL SITE FOR THE GENERAL PUBLIC IN JAPAN

E. Arita\* (JP) - A. Ujihara - Y. Majima - I. Yamaguchi - T. Genshin - K. Hoshi - Y. Nishibata - H. Yamasaki - T. Watanabe - N. Tanabe

► **PP169**

PIOGLITAZONE IN MILD TO MODERATE ULCERATIVE COLITIS: A PLACEBO CONTROLLED RANDOMIZED TRIAL

B. Medhi\* (IN) - S. Kaur - S. C. Sarangi - A. Prakash - U. Dutta - R. KOCHHAR

► **PP172**

SHORT-TERM IMPACT OF BARIATRIC SURGERY ON OBESITY ASSOCIATED DIABETES MELLITUS

C. Kumana\* (CN) - B. M. Cheung - K. Tan

► **PP173**

CYTISIN AMIDOPHOSPHATE SHOWS HEPATOPROTECTIVE EFFECT

T. Nurgozhin\* (KZ) - A. Gulyaev - A. Gazaliyev

► **PP175**

EVIDENCE OF DRUG-DRUG INTERACTIONS THROUGH UPTAKE AND EFFLUX TRANSPORT SYSTEMS IN RAT HEPATOCYTES: IMPLICATIONS FOR CELLULAR CONCENTRATIONS OF COMPETING DRUGS

Y. Daali\* (CH) - P. Millet - P. Dayer - C. Pastor

► **PP176**

COMPARISON OF INHIBITORY DURATION OF GRAPEFRUIT JUICE ON ORGANIC ANION-TRANSPORTING POLYPEPTIDE AND CYP3A4

S. Tanaka\* (JP) - S. Uchida - S. Miyakawa - N. Inui - K. Takeuchi - H. Watanabe - N. Namiki

► **PP177**

INHIBITORY INTERACTION OF 125 DRUGS WITH THE RENALLY EXPRESSED ORGANIC CATION TRANSPORTER OCT2: DEVELOPMENT OF A CHEMOINFORMATICS-BASED MODEL TO PREDICT TRANSPORTER INHIBITION IN SILICO

K. Münch\* (DE) - J. Schwöbel - O. Zolk - R. Maas - L. Terfloth - M. F. Fromm

► **PP178**

ANTIEPILEPTIC DRUGS: PRESCRIBING PATTERNS AND INTERACTION RISK IN GENERAL PRACTICE

D. Italiano\* (IT) - R. Ferrara - G. Trifirò - S. Gagliostro - G. Starvaggi - C. Pagliaro - I. Lombardi - M. Tarì - A. Capuano - E. Spina - V. Arcoraci

► **PP179**

IDENTIFICATION OF DRUG-DRUG INTERACTIONS THROUGH A DIGITAL HEALTH SERVICE

S. Ussai\* (IT) - A. Casetta - F. Pisa - G. Trillò - R. Petelin - F. Barbone - A. Degrossi - G. Giagnorio

► **PP180**

ROLE OF ORGANIC ANION TRANSPORTING POLYPEPTIDES 1A2 AND 2B1 IN CELLULAR UPTAKE OF NADOLOL

S. Misaka\* (DE) - F. Müller - H. Glaeser - J. König - M. F. Fromm

► **PP181**

EVALUATION OF THE INTERACTION BETWEEN METHOTREXATE AND PROTON PUMP INHIBITORS USING HUMAN OAT1 AND OAT3 HEK TRANSFECTED CELLS

R. Chioukh - M.-S. Noel-Hudson - S. Ribes - N. Fournier - L. Becquemont - C. Verstuyft\* (fr)

► **PP183**

EFFECT OF RITONAVIR, KETOCONAZOLE AND RIFAMPIN ON INTESTINAL AND HEPATIC CYTOCHROME P450 3A ENZYMES IN HEALTHY ASIAN ADULTS

K.-Y. Seng - K. H. Hee - L. S.-U. Lee\* (SG)

► **PP186**

THE ANALYSIS OF INTERACTION OF WARFARIN IN THE REAL CLINICAL PRACTICE

R. Barakanova\* (KG) - U. Tilekeeva

► **PP189**

A PHYSIOLOGICALLY-BASED MECHANISTIC PHARMACOKINETIC MODEL TO ASSESS THE METABOLISM OF OXYCODONE IN HEALTHY VOLUNTEERS: INTERPLAY BETWEEN CYP3A AND 2D6 INHIBITION

N. Marsousi\* (CH) - Y. Daali - H. Humphries - L. Almond - P. Dayer - J. Desmeules - C. Samer

► **PP191****INFLUENCE OF VERAPAMIL ON THE PHARMACOKINETICS OF OXCARBAZEPINE AND 10-HYDROXYCARBAZEPINE ENANTIOMERS IN HEALTHY VOLUNTEERS**

N. D. J. Antunes\* (BR) - L. Wichert-Ana - E. B. Coelho - O. Della Pasqua - V. Alexandre Junior - O. M. Takayanagui - V. L. Lanchote

► **PP192****PHARMACOKINETICS OF SELEXIPAG IN SUBJECTS WITH SEVERE RENAL IMPAIRMENT COMPARED TO HEALTHY SUBJECTS**

N. Fischer\* (CH) - H. Cruz - S. Bruderer - M. Petersen-Sylla - A. Halabi - J. Dingemanse

► **PP193****SIMULTANEOUS LC-MS/MS QUANTIFICATION OF P-GLYCOPROTEIN AND CYTOCHROME P450 PROBE SUBSTRATES AND THEIR METABOLITES IN DRIED BLOOD SPOTS**

M. Bosilkovska\* (CH) - J. Deglon - C. Samer - B. Walder - P. Dayer - J. Desmeules - C. Staub - Y. Daali

► **PP194****PHARMACOKINETICS OF SELEXIPAG IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT COMPARED TO HEALTHY SUBJECTS**

N. Fischer\* (CH) - P. Kaufmann - S. Bruderer - I. Ulč - J. Dingemanse

► **PP195****VORICONAZOLE ADJUSTMENT FROM TWICE TO THREE TIMES DAILY IN CYSTIC FIBROSIS LUNG TRANSPLANT PATIENTS**

L. Tanneau - G. Deslandes\* (FR) - T. Lepoivre - D. Bouteille - R. Bouquie - E. Dailly - P. Joliet

► **PP196****ENANTIOSELECTIVE METABOLISM OF VENLAFAXINE IN HEALTHY VOLUNTEERS AND IN PATIENTS WITH PSORIASIS**

V. L. Lanchote\* (BR) - A. L. P. C. Godoy - C. D. Silva Souza - E. B. Coelho - A. Rocha - E. Tozatto

► **PP197****THERAPEUTIC DRUG MONITORING OF VANCOMYCIN AND AMINOGLYCOSIDES IN AN INTENSIVE CARE UNIT, A RETROSPECTIVE STUDY**

K. R. Ing Lorenzini\* (CH) - C. Samer - J. Pugin - S. Harbarth - P. Bonnabry - M. Fathi - P. Dayer - J. Desmeules

► **PP198****PHARMACOKINETICS OF IMIPENEM IN THE TREATMENT OF NOSOCOMIAL PNEUMONIA: COMPARISON OF 0.5 HR AND 3 HR INFUSION**

H. Suchánková\* (CZ) - M. Lipš - M. Šiller - J. Strojil - K. Urbánek

► **PP199****INTRACELLULAR CONCENTRATION OF DARUNAVIR AS AN INDICATOR FOR THE CLINICAL EFFICACY IN HIV PATIENTS**

D. Nagano\* (JP) - T. Araki - K. Yanagisawa - T. Hayashi - Y. Ogawa - Y. Nojima - T. Nakamura - K. Yamamoto

► **PP200****METABOLIC PROCESS OF VORICONAZOLE TO ITS N-OXIDE IS SATURABLE IN CLINICAL DOSE RANGE**

T. Yamada\* (JP) - Y. Mino - T. Yagi - T. Naito - J. Kawakami

► **PP201****AN OPEN-LABEL, RANDOMIZED, SINGLE-CENTRE, FOUR-WAY CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF SINGLE, ORAL DOSES OF RETIGABINE/EZOGABINE IN HEALTHY ADULT TAIWANESE SUBJECTS**

M. Buraglio\* (GB)

► **PP202****CANCER CACHEXIA RAISES THE PLASMA CONCENTRATION OF OXYMORPHONE THROUGH THE REDUCTION OF CYP3A BUT NOT CYP2D6 IN OXYCODONE-TREATED PATIENTS**

T. Naito\* (JP) - M. Tashiro - T. Ishida - K. Ohnishi - J. Kawakami

► **PP203****WHOLE BLOOD CANNABINOID PHARMACOKINETIC PARAMETERS IN HEAVY AND OCCASIONAL SMOKERS. DO ORAL FLUID CANNABINOID MEASUREMENTS CORRELATE WITH WHOLE BLOOD DATA IN HEAVY SMOKERS?**

M. Fabritius\* (CH) - E. Lauer - H. Chtioui - M. Appenzeller - P. Mangin - C. Staub - C. Giroud

► **PP204****METHADONE KINETICS AND CORRECTED QT TIME DURING HAEMODIALYSIS IN FOUR METHADONE MAINTENANCE TREATMENT PATIENTS WITH END-STAGE RENAL FAILURE**

M. S. Opdal\* (NO) - M. Arnesen - K. Sayed - S. Sagedal - K. Gjesdal - L. D. Müller - M. Kringen - O. Brørs - P. Krajci

► **PP205****COMPARISON OF PHARMACODYNAMIC EFFECT OF TWO DIFFERENT MODIFIED-RELEASE ORAL DILTIAZEM FORMULATIONS**

M. Bogiel\* (PL) - M. Pawłowska - J. Duda - E. Sieradzki

► **PP207****PHARMACOKINETICS OF SUGAMMADEX 16 MG/KG IN CHINESE SUBJECTS**

P.-J. de Kam\* (US) - J. Hou - Z. Wang - W. H. Lin - P. Grobara - M. van den Heuvel



► **PP208**

**DEOXYCHOLIC ACID AS A MODIFIER OF THE BLOOD BRAIN BARRIER PERMEATION IN RAT**

M. Lalic-Popovic\* (RS) - S. Golocorbin-Kon - V. Vasovic - B. Milijasevic - M. Mikov

► **PP209**

**MODEL-BASED ANALYSIS OF THE PHARMACOKINETICS OF A MODIFIED RELEASE FORMULATION OF PARACETAMOL AFTER TWICE DAILY DOSING AND POTENTIAL IMPLICATIONS FOR THE RISK OF HEPATOTOXICITY IN OSTEOARTHRITIS PATIENTS**

O. Della Pasqua\* (GB) - K. Bergman - J. de Jongh

► **PP210**

**PHARMACOKINETICS AND PHARMACODYNAMICS MODELING TO OPTIMIZE DOSAGE REGIMENS OF SULBACTAM**

S. Jaruratanasirikul\* (TH) - W. Wongpoowarak - N. Aeinlang - M. Jullangkoon

► **PP211**

**PIPERINE INCREASES PLASMA DOMPERIDONE CONCENTRATIONS IN THE RAT**

M. Alhumayyd\* (SA) - I. Bukhari - A. Almotrefi

► **PP212**

**BIOAVAILABILITY OF DIGOXIN TABLETS, LOW THERAPEUTIC INDEX DRUG, DETERMINED BY EMIT**

J. Duda\* (PL) - M. Pawłowska - M. Bogiel - B. Tejchman-Matecka - E. Sieradzki

► **PP213**

**CORRELATION OF DISSOLUTION DATA WITH CLINICAL EFFICACY OF TWO LAMOTRIGINE TABLET FORMULATION**

M. Lalic-Popovic\* (RS) - S. Golocorbin-Kon - V. Vasovic - B. Milijasevic - M. Mikov

► **PP214**

**TACROLIMUS BLOOD CONCENTRATION IN PATIENTS SUBJECTED TO RENAL TRANSPLANTATION: THE INFLUENCE OF GENDER**

N. Rancic - N. Vavic - A. Kovacevic\* (RS) - V. Dragojevic-Simic - B. Draskovic-Pavlovic - D. Bokanjic - L. Ignjatovic - M. Mikov

► **PP215**

**PHARMACOKINETIC STUDY OF GANCICLOVIR (GCV) AFTER SINGLE AND MULTIPLE DOSE IN HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) PATIENTS WITH CYTOMEGALOVIRUS (CMV) INFECTION**

S. M. Awada\* (LB)

► **PP217**

**CORRELATION BETWEEN IN VITRO TESTS FOR BLOOD BRAIN BARRIER PENETRATION WITH IN VIVO GLICLAZIDE PENETRATION**

M. Lalic-Popovic\* (RS) - V. Vasovic - H. Al-Salami - S. Golocorbin-Kon - B. Milijasevic - M. Mikov

► **PP219**

**THIOPURINE METABOLITES ARE USEFUL IN PREDICTING AZATHIOPRINE RESISTANCE IN PEDIATRIC IBD PATIENTS**

T. V. A. Nguyen - T. M. H. Nguyen - A. Lachaux - R. Boulieu\* (FR)

► **PP220**

**THE RISK OF BIRTH DEFECTS FOLLOWING EXPOSURE TO NITROFURANTOIN DURING FIRST TRIMESTER**

O. J. Goldberg\* (IL) - D. Landau - G. Koren - E. Lunenfeld - I. Matok - A. Levy and BeMORE collaboration (Ben-Gurion Motherisk Obstetric Registry of Exposure collaboration)

► **PP221**

**DRUG USE IN THE PAEDIATRIC WARDS IN DENMARK – A NATIONWIDE STUDY WITH FOCUS ON LEGISLATION**

S. S. Haslund-Krog\* (DK) - R. Mathiasen - H. Rolighed Christensen - H. Holst

► **PP222**

**THERAPEUTIC DRUG MONITORING OF DAPTOMYCIN: A RETROSPECTIVE MONOCENTRIC ANALYSIS**

C. Reiber - O. Senn - D. Müller - G. A. Kullak-Ublick - N. Corti\* (CH)

► **PP223**

**PERCEPTIONS TOWARDS BENZODIAZEPINE DISCONTINUATION IN NURSING HOMES**

J. Bourgeois\* (BE) - M. Elseviers - M. Azermi - L. Van Bortel - M. Petrovic - R. Vander Stichele

► **PP224**

**VIEWS OF CLINICAL AND NON-CLINICAL PROFESSIONALS ON INFORMATION ABOUT OLDER PATIENTS NEEDED FOR RATIONAL DRUG PRESCRIPTION AT TIME OF AUTHORISATION**

E. Beers\* (NL) - A. C. Egberts - H. G. Leufkens - P. A. Jansen

► **PP226**

**AVAILABLE AND CLINICALLY APPLICABLE INFORMATION FOR RATIONAL PRESCRIBING TO OLDER PATIENTS IN EUROPEAN AND AMERICAN HANDBOOKS**

J. L. Boer - E. Beers\* (NL) - T. C. Egberts - H. G. Leufkens - P. A. Jansen



► **PP227**

**CHRONIC TREATMENT WITH PRAVASTATIN IMPROVES THE IMPAIRED NITRIC OXIDE – MEDIATED NEUROGENIC AND ENDOTHELIUM-DEPENDENT RELAXATION OF CORPUS CAVERNOSUM IN AGED RATS**

S. Dalaklioglu - P. Sahin - A. Tasatargil\* (TR) -  
C. Celik-Ozenci

► **PP228**

**ADVERSE REACTIONS IN CHILDREN ARE NOT THE SAME IN ADULTS: ANALYSIS OF SPONTANEOUS REPORTS IN 2011-2012 IN CRIMEA, UKRAINE**

O. V. Matvieiev\* (UA)

► **PP229**

**OBSERVATIONS ON THE OXALIS PERDICARIA (MOLINA) BERTERO IN CHILDREN WITH THE PERSISTENT MALNUTRITION DIARRHEA: RANDOMIZED CONTROLLED CLINICAL TRIAL**

M. A. H. Mollik\* (BD)


► **PP230**

**PATTERN OF PARENTERAL DRUG PRESCRIPTION FOR CHILDREN UNDER THE AGE OF 6 IN TURKEY**

B. Donertas - A. Gelal\* (TR) - A. Alkan - S. Mollahaliloglu -  
A. Akici

► **POSTER GUIDED TOUR**

**SATURDAY  
31 AUGUST  
2013**

 10:30 – 11:15

► **PP231**

**ACUTE HUMAN TOXICITY OF THIOPURINES, MYCOPHENOLATE AND SIROLIMUS**

C. Gregoriano - A. Ceschi - C. Rauber-Lüthy - H. Kupferschmidt - S. Krähenbühl - A. Taegtmeyer\* (CH)

► **PP232**

**ACUTE TOXICITY PROFILE OF PIPAMPERONE IN OVERDOSE: A CONSECUTIVE CASE SERIES**

K. E. Hofer\* (CH) - C. Rauber-Lüthy - H. Kupferschmidt -  
G. A. Kullak-Ublick - A. Ceschi

► **PP233**

**CYP1A ACTIVITY AFTER CHRONIC EXPOSURE TO DIOXINS FROM A WASTE INCINERATOR**

C. Samer\* (CH) - F. Doffey-Lazeyras - O. Sorg -  
J.-H. Saurat - P. Dayer - Y. Daali - J. Desmeules

► **PP234**

**INTOXICATION WITH ATYPICAL ANTIPSYCHOTICS IN YOUNG CHILDREN: A MULTICENTRE ANALYSIS OF POISONS CENTRES DATA**

M. Meli\* (CH) - C. Rauber-Lüthy - P. Hoffmann-Walbeck -  
H.-J. Reinecke - D. Prasa - U. Stedtler - E. Färber - G. Dieter -  
H. Kupferschmidt - G. A. Kullak-Ublick - A. Ceschi

► **PP237**

**EVALUATION OF THE EFFECT OF DIMETHOATE INTOXICATION ON MALE RAT REPRODUCTIVE PERFORMANCES**

J. M. El-Medany\* (EG) - A. M. El-Medany - A. A. Guemei -  
Y. A. Bassioni

► **PP238****SYNTHESIS OF THE FIVE BANGLADESHI UNANI MEDICINES DERIVATIVES: IN VITRO STUDIES OF THEIR PHARMACOLOGICAL ACTIVITIES**

M. A. H. Mollik\* (BD)

► **PP239****SUSCEPTIBILITY OF LEPTOSPIRA TO XANTHONES AND SYNERGISTIC EFFECTS WITH ANTIBIOTICS**

C. Mekseepalard\* (TH) - W. Seesom - S. Suksumran - P. Ratananukul - T. Kammee - W. Sukhumsirichart

► **PP240****PHARMACEUTICAL QUALITY OF GENERIC LEVODOPA/BENSERAZIDE PRODUCTS**

G. L. Vital-Durand\* (CH) - I. Arnet - U. E. Gasser - A. Fischer

► **PP241****POTENTIAL EFFECT OF THE MEDICINAL PLANTS; CALOTROPIS PROCERA, FICUS ELASTICA AND ZINGIBER OFFICINALE AGAINST SCHISTOSOMA MANSONI IN MICE**

S. S. Botros\* (EG) - S. H. Seif el-Din - N. M. El-Lakkany - M. A. Mohamed - M. M. Hamed - O. Sterner

► **PP243****THE POTENTIAL ANTICANCER EFFECT OF AZO DYES**

L. Harmse\* (ZA) - S. Moch - H. Motau

► **PP244****THERAPEUTIC AND SUPRA-THERAPEUTIC INTRAVENOUS DOSES OF MAVOGLURANT (AFQ056) DO NOT PROLONG THE QTC INTERVAL IN HEALTHY SUBJECTS**

M. Ufer\* (CH) and A. Tisserant, A. Dodman, E. Voltz, A. Salunke, R. Woessner, A. Sagkriotis, P. Jordaen, E. Legangneux

► **PP245****IN-VITRO BIOASSAY OF 1,5 - DIMETHYL CITRATE MONOHYDRATE; A COMPOUND ISOLATED FROM THE FRUIT OF MANGIFERA INDICA (ANACARDIACEAE)**

F. Khan\* (NG) - E. olowononi - M. Garba - A. Iawal

► **PP248****MELITOR® - REGULATORY ISSUES AS PREREQUISITE FOR PUTTING DRUG ON THE MARKET**

V. Stanimirovic\* (RS) - D. NIKOLIC - A. Nikolic - B. Stanimirovic - M. Lisicic

► **PP249****BRINAVESS® - ARGUMENTS OF REGULATORY SUSPENSION IN SERBIA**

V. Stanimirovic\* (RS) - D. NIKOLIC - A. Nikolic - B. Stanimirovic - M. Lisicic

► **PP252****ETHICS OF RELATIONSHIPS IN THE SPHERE OF PHARMACEUTICAL SERVICES**

E. Abdulkharova\* (KG) - A. Zurdinov

► **PP255****IFN-GAMMA INTERFERE THE EFFECT OF BETA-2 AGONIST ON TNF-ALPHA INDUCED CXCL10 THROUGH CREB PHOSPHORYLATION IN HASM CELLS**

S. Jindarat\* (TH) - D. L. Clarke - R. Clifford - A. E. John - A. J. Knox

► **PP256****COMPARATIVE STUDY BETWEEN ANGIOTENSIN INHIBITORS & THEIR RECEPTOR BLOCKERS ON ULCERATIVE COLITIS IN RATS**

J. H. Elmedany\* (SA) - A. H. El-Medany - H. I. Hagar

► **PP257****CHLOROGENIC ACID AS POTENTIAL ANTI-INFLAMMATORY ANALGESIC AGENT**

A. M. El-Medany\* (EG) - Y. A. Bassiouni - M. M. Khattab - A. A. Mahesar

► **PP259****THE ABILITY OF ANTI-S100 ANTIBODIES TO AMELIORATE THE SEVERITY OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN WISTAR RATS**

J. L. Dugina\* (RU) - I. N. Abdurasulova - I. A. Ertuzun - O. I. Epstein

► **PP261****UTILIZATION OF TRIPTANES IN SWEDEN; ANALYSES OF OVER THE COUNTER AND PRESCRIPTIONS SALES**

M. Von Euler\* (SE) - S. Keshani - K. Baatz - B. Wettermark

► **PP262****CAN AUTHORITIES TAKE FULL ADVANTAGE OF THE AVAILABILITY OF GENERIC ATYPICAL ANTIPSYCHOTIC DRUGS? IMPLICATIONS FOR THE FUTURE**

B. Godman\* (SE) - M. Persson - J. Miranda - C. Barbui - M. Bennie - K. Bennett - A. Buccics - S. Simoens - C. Zara - L. L. Gustafsson

► **PP263****IMPORTANCE OF TDM, PHENOTYPING AND GENOTYPING DURING INTOXICATION WITH VENLAFAXINE**

I. Kacirova\* (CZ) - M. Grundmann - R. Urinovska - P. Silhan

► **PP264****4-METHYLESCULETIN A DUAL ACTING INHIBITOR OF ACETYLCHOLINESTERASE AND XANTHINE OXIDASE**

T. Shirole\* (IN) - E. Martis - D. Makhija - R. Pissurlenkar - A. Jagtap - E. Coutinho

► **PP265****ATTENUATION OF ALUMINIUM INDUCED NEURODEGENERATION BY 4-METHYLESCULETIN**

T. Shirole\* (IN) - D. Makhija - A. Jagtap

► **PP266****IMPROVED BEHAVIOUR OF APPSW 2576 ALZHEIMER'S DISEASE TRANSGENIC MICE ON LONG TERM SUPPLEMENTATION OF FIGS IN THEIR DIET**

M. Essa - S. Subhash - R. Vaishnav\* (OM) and Ageing and Dementia Research Group, Sultan Qaboos University, Muscat, Oman.

► **PP268****DRUG-INDUCED LONG QT IN ADULT PSYCHIATRIC INPATIENTS: THE 5-YEAR CROSS-SECTIONAL ESOP STUDY**

F. R. Girardin\* (CH) - M. Gex-Fabry - P. Berney - D. Shah - J.-M. Gaspoz - P. Dayer

► **PP269****INTEREST OF GENOTYPE ASSESSMENT IN ANTIDEPRESSANT TREATMENT FAILURE IN PSYCHIATRIC PATIENTS: A CASE REPORT**

F. Rodieux\* (CH) - A. Zavodnik - Y. Daali - V. Rollason - K. Gomez-Padra - N. Fuertes-Fernandez - J. Desmeules - M. Besson

► **PP270****COMPUTATIONAL MODELING OF DRAVET SYNDROME**

P. Kurbatova\* (FR) - P. Benquet - F. Wendling - C. Cornu - R. Guerrini - A. Kaminska - O. Dulac - G. Pons - R. Nabbout - C. Chiron - P. Nony

► **PP271****NOVEL THERAPEUTIC STRATEGY TO PREVENT CHEMOTHERAPY-INDUCED PERSISTENT SENSORY NEUROPATHY BY TRPA1 BLOCKADE**

G. Trevisan - S. Materazzi - C. Fusi - A. Altomare - G. Aldini - R. Patacchini - P. Geppetti - R. Nassini\* (IT)

► **PP272****MIGRAINE AND PARTHENOLIDE INHIBITION OF TRANSIENT RECEPTOR POTENTIAL ANKYRIN 1**

S. Materazzi - S. Benemei\* (IT) - C. Fusi - G. De Siena - G. Trevisan dos Santos - G. Dussor - F. Pollastro - R. Patacchini - G. Appendino - P. Geppetti - R. Nassini

► **PP273****EFFECT OF THE GABAA LIGANDS CLOBAZAM AND CLONAZEPAM ON THE MODULATION OF PAIN TRANSMISSION IN HUMANS: A PK-PD STUDY**

M. Besson\* (CH) - A. Matthey - D. Youssef - P. Vuillemier - M. Curatolo - P. Dayer - H. U. Zeilhofer - J. Desmeules

► **PP274****MEMANTINE PREVENTS THE DEVELOPMENT OF NEUROPATHIC PAIN WHEN GIVEN BEFORE SURGERY**

G. Pickering\* (FR) - V. Morel - L. Terrail

► **PP275****CHITOSAN/POLYMER NANOPARTICULATE CONTROLLED RELEASE SYSTEM FOR IBUPROFEN**

B. I. Tamba\* (RO) - V. Streinu - D. Iurea - M. Popa - J.-F. Chailan - C. Peptu

► **PP277****INCREASE IN MORPHINE ANALGESIC EFFECT WHEN CO-ADMINISTRATED WITH BILE ACID DERIVATES**

V. Vasovic\* (RS) - S. Vukmircovic - M. Mikov - I. Mikov - Z. Budakov - N. Stilinovic - B. Miliasevic

► **PP278****BILE ACID INDUCED CHANGES IN THE EXPRESSION OF MIRNAS AND GENES INVOLVED IN DRUG METABOLISM AND DISPOSITION**

J. Winyi\* (CH) - W. E. Thasler - G. A. Kullak-Ublick

► **PP279****CARDIO-HEPATIC SYNDROME AND THERAPEUTIC EFFICACY OF NAD-CONTAINING DRUG**

N. V. Gongadze\* (GE) - M. A. Rogava - T. M. Bochorishvili - T. D. Kezeli - N. P. Mitagvari - M. K. Chipashvili - N. M. Dolidze - G. V. Sukoyan

► **PP280****BLOOD LEVELS OF CYCLOSPORINE A AND ITS FIRST LINE METABOLITES DURING AN EARLY FASE AFTER RENAL TRANSPLANTATION IN PATIENTS WITH NORMAL AND DELAYED GRAFT FUNCTION**

M. Grundmann\* (CZ) - P. Halvova - H. Brozmanova - J. Dedochova - A. Martinek

► **PP281****INTRAVENOUS STREPTOMYCIN DOSING REGIMEN IN A PATIENT UNDERGOING HEMODIALYSIS: PLASMA LEVEL MONITORING AND PHARMACOKINETIC SIMULATION**

H. Chtioui\* (CH) - D. Zbinden - O. Manuel - J. Entenza - L. A. Decosterd - T. Buclin

► **PP282****THE ROLE OF CBS AND H<sub>2</sub>S IN THE INDUCTION OF TORPOR AND ORGAN PRESERVATION DURING HIBERNATION**


G. J. Dugbartey\* (NL) and Prof. Dr. Robert H. Henning

► **PP283****MOTOR AND BEHAVIORAL CHANGES IN MICE WITH CISPLATIN-INDUCED ACUTE RENAL FAILURE**


A. Ramkumar\* (OM) - T. T. Madanagopal - S. Al-Abri - M. I. Waly - M. Tageldin - M. Fahim - A. Nemmar - B. H. Ali



► **PP284****EFFECT OF DIESEL EXHAUSTS PARTICLES ON CISPLATIN-INDUCED TOXICITY ON HUMAN KIDNEY CELLS, AND THE INFLUENCE OF CURCUMIN THEREON**

B. H. Ali\* (OM) - M. I. Waly - A. Nemmar



CONGRESS CENTRE FLOOR PLAN















## Innovating for better medicines

At Novartis, we want to discover, develop and provide high-quality healthcare solutions to address the evolving needs of patients and societies worldwide. We believe that our diverse healthcare portfolio, our dedication to innovation, and our responsible approach will enable us to fulfill our mission to care and to cure.